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Abstract
Approximately one in a hundred people suffer from schizophrenia. Symptoms are partially
improved by medication but most symptoms are lifelong. There is no cure. The causes and
mechanisms are still unknown. Glutamate, an excitatory neurotransmitter, is a possible cause
of the schizophrenia symptoms. Excessive glutamate levels eventually lead to the
neurodegeneration. Longitudinal studies are necessary to observe the neurodegenerative
process.
Seventeen first episode schizophrenia patients and 17 comparable healthy volunteers
underwent a longitudinal study using proton magnetic resonance imaging and spectroscopy
to measure structural and neurochemical changes in vivo. Metabolite levels were measured
from a 1.5cm3 voxel in the left anterior cingulate and the left thalamus using the stimulated
echo acquisition mode sequence (STEAM). Gray matter in the entire brain was examined
with a voxel-based morphometry using the Statistical Parametric Mapping.
Total glutamatergic metabolite levels (tGL), N-acetylaspartate (NAA) levels, and gray matter
were significantly decreased in schizophrenia over 80 months. Reduced tGL and NAA levels
were significantly correlated with gray matter loss in areas related to schizophrenic
symptoms. Loss of tGL levels was negatively correlated with social functioning measure.
Significantly decreased tGL levels were possibly associated with gray matter loss in the
voxel of interest. The metabolite signal-to-noise ratio decreased as a function of MR system
age, but that did not significantly affect the findings presented in this thesis.
These findings demonstrate the feasibility of long-term MRS studies of neurological
disorders and have a number of implications for the understanding of the pathophysiology of
schizophrenia. Changes in glutamatergic metabolites and gray matter losses were consistent
with neurodegeneration. The effects of an early neurodevelopmental lesion leading to
glutamatergic abnormalities at the onset of illness or the effects of chronic medication could
not be ruled out.
Structural and metabolite changes in these patients over the early years of illness have
implicated glutamate as a possible target of therapeutic intervention in this disorder. Current
iii

treatments do not prevent deterioration of their social skills. The association between the loss
of glutamatergic metabolites and social functioning in this study suggests that it might be
possible to arrest this process with pharmaceuticals that target glutamate.

Keywords
glutamate, glutamine, excitotoxicity, N-acetylaspartate, social functioning,
neurodegeneration, signal-to-noise ratio, longitudinal study
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Chapter 1

1

Introduction

1.1 Schizophrenia
Schizophrenia is a severe mental disorder, which was first referred to as dementia
praecox by Emil Kraepelin in 1896.1 He noticed that some psychotic patients had a
deteriorating course similar to patients with dementia while the others recovered. The
latter group was referred to as manic depressive patients. Later, Eugen Bleuler introduced
the term schizophrenia,2 highlighting the disturbed “sense of self” noticeably present in
the disorder. Major symptoms of schizophrenia described in the DSM IV criteria3 are
classified as positive symptoms (e.g. hallucination and delusions), negative symptoms
(e.g. social withdrawal and flat emotion) and cognitive symptoms (e.g. poor attention and
executive functioning). Positive symptoms are usually suppressed with the antipsychotic
drugs while negative symptoms are not improved as much with these medications. Thus
far, there is no cure for schizophrenia and its causative mechanism is unclear.
There have been many epidemiological and genetic studies of schizophrenic patients.
Research has shown that a family member of schizophrenic patients is more likely to
develop the disease than the general population. In the case of monozygotic twins, the
chance of developing schizophrenia increases to 50 percent when the other suffers from
schizophrenia.4 If someone is a first degree relative, the risk is about 10 percent compared
to about 1 percent in the general population. A few groups reported that the number of
schizophrenia patients born during a flu epidemic in 1957 was significantly higher than
the general population.5 Other studies have found increased risk of schizophrenia
associated with obstetrical complications6 such as bleeding in pregnancy. Thus,
schizophrenia is a complex disorder with both genetic and environmental factors
contributing.
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1.1.1

Pathological evidence

From post mortem studies, abnormalities in nerve cells in schizophrenia were found such
as pyramidal cell disarray in the hippocampus, associated with long-term memory.7
Pakkernberg8 found decreased total neuronal number in the mediodorsal thalamus, a
central sensory processing region in the human brain. Selemon et al.9 showed higher
neuronal density in the prefrontal cortex in schizophrenia compared to the normal human
brain, suggesting a potential malfunction in higher order processing. In other studies,
significantly decreased GABAergic interneurons were seen in schizophrenia.10 GABA
(gamma aminobutryric acid) is an inhibitory neurotransmitter, which mediates the
glutamatergic signals in the brain.11,12 Significantly decreased glutamic acid
decarboxylase (GAD)67 expression was seen in the brain tissues of schizophrenia
subjects. GAD67 protein is produced when GABA is synthesized from glutamate, an
excitatory neurotransmitter in the brain. Significant GAD67 reduction has been reported
in the prefrontal cortex in this patient population.13 Akbarian et al. found that cell
migration in the prefrontal cortex and hippocampus occurred in deeper area in
schizophrenia compared to controls.14,15 These postmortem findings and Falkai et al.16
suggest an abnormality in the brain developmental process affecting cortical structure.
However, postmortem studies have a number of limitations such as the confounding
effects of medication, aging and other medical illnesses.

1.1.2

Brain imaging (CT, MRI)

Recent developments in neuroimaging have facilitated the in vivo examination of patients
and controls. The most consistent finding has been the larger size of the lateral ventricles
in chronic schizophrenic patients. This abnormality was found in studies using computed
tomography (CT)17 and magnetic resonance imaging (MRI).18 In terms of the anatomical
structure, a reduction in size in schizophrenia compared to controls has been reported in
several regions including the dorsolateral prefrontal cortex, hippocampus, thalamus,
anterior cingulate and superior temporal gyrus.19
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Gray matter losses in schizophrenia, compared to normal subjects, were observed in
several regions in the brain such as the frontal cortex, dorsolateral prefrontal regions,
hippocampus, and superior temporal gyrus.19 However, findings in gray matter loss have
not been consistent in terms of the brain region. Thompson et al.20 examined gray matter
loss in schizophrenia subjects and healthy controls over five years. They showed a
significant reduction in cortical gray matter in schizophrenia subjects compared with
controls. This study and several similar longitudinal studies21,22 imply that
neuroanatomical abnormalities in schizophrenia may be progressive.17

1.1.3

Functional connectivity

Besides the structural abnormalities in schizophrenia, there has also been research to
examine the functional connectivity in the brain. Diffusion tensor imaging (DTI)
techniques provide a view of the connectivity in the brain regions, inferring the
directional connectivity through the measurement of the apparent diffusion coefficient
(ADC).23 Many studies have shown the increased myelin density in the white matter,
suggesting a complex functional connectivity in schizophrenia.24 Functional MRI (fMRI)
has shown a functional disconnectivity in schizophrenia such as in default network
studies.25 A default network is considered to be the basic functional connectivity in the
resting state of the normal brain. A few studies of the default network showed that some
of the functional connections are abnormal in schizophrenia.26 Bluhm et al.27 reported
that functional connectivity from the posterior cingulate is significantly weaker or
unidentified in the first episode schizophrenia patient when compared to healthy
volunteers.
Thus, there are a number of structural and functional abnormalities found in many brain
regions in schizophrenia patients. The heterogeneity of these findings points to a number
of genetic and environmental factors, all of which may affect final common pathways
leading to the symptoms of schizophrenia. Among possible final common pathways,
limbic basal ganglia thalamocortial circuits have been the most studied.28
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1.1.4

Candidate circuit: Basal ganglia-thalamocortical circuit

The central nervous system is composed of billions of nerve cells (neurons). The signals,
such as sensory information, are transmitted as electric stimuli with neurotransmitters,
which are biochemical compounds, pooled in the axon terminals.

Figure 1-1: Limbic basal ganglia thalamocortical circuit
AC, anterior cingulate; Cb, cerebellum; Hip, hippocampus; NA, nucleus
accumbens; Pfc, prefrontal cortex; Th, thalamus; VT, ventral tegmentum. (This
illustration is adapted from Figure 2-2 in [29])
Figure 1-1 represents one potential candidate neuronal circuit implicated in schizophrenic
anomalies, called the limbic basal ganglia thalamocortical (BGTC) circuit. This BGTC
circuit, one of the basic neuronal pathways in the normal human brain, is considered to be
a possible candidate circuit for schizophrenia because this circuit is responsible for the
connections between the brain regions related to schizophrenic symptoms. The anterior
cingulate is associated with attention and emotional processing.30 The thalamus is
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considered to be a gateway to the brain since all neuronal signals except olfactory
information pass through this region. Most of the connections are glutamatergic.
Glutamate is an amino acid found in many areas of the body, but is abundant in the
nervous system where it is a major excitatory neurotransmitter. The understanding from
this candidate circuit in local abnormalities will be extended to the entire brain
encompassed by the neuronal pathways. For instance, if significantly higher or lower
glutamate is observed in the thalamus, it may result in malfunction of the entire candidate
circuit, composed of glutamatergic connections.
Another important excitatory neurotransmitter associated with the BGTC is dopamine. In
this BGTC, dopaminergic neurons project from the ventral tegmentum to the nucleus
accumbus which is an important node in this pathway. Currently, most medication for
schizophrenia targets the dopamine neurotransmission.31 Since schizophrenic positive
symptoms are improved with these medications, dopamine is thought to be a key
neurotransmitter implicated in this disorder.32

1.1.5

Etiological theories of schizophrenia

As indicated above, the glutamate and dopamine theories are good candidates for
investigations to elucidate possible mechanisms of schizophrenia. From a
pathophysiological point of view, these two hypotheses of schizophrenia will be
discussed below. The Dopamine Hypothesis is suggested through the effect of
antipsychotic medication that suppresses psychosis by blocking the dopamine receptor.32
The Glutamate Hypothesis is suggested by the results of drugs that cause glutamate
receptor hypofunction. In normal and schizophrenic subjects these drugs induce both
psychotic symptoms (e.g. hallucinations) and negative symptoms (e.g. flat affect and lack
of motivation). While the Glutamate Hypothesis has some advantages, there is not a large
amount of direct evidence suggesting that glutamate is the major cause of schizophrenia.
It is also possible that both dopamine and glutamate may be involved in the
pathophysiology of schizophrenia.
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1.1.5.1

Dopamine hypothesis

The abuse of drugs that stimulate dopamine often causes hallucinations and delusions that
resemble the positive symptoms of schizophrenia.33 Dopamine is one of the major
excitatory neurotransmitters, associated with several functions such as motor activity,
attention and reward.34 Positron emission tomography studies have shown an increased
dopamine re-uptake, compared to a control group, in the D2 receptor at the ventral
tegmentum in schizophrenic subjects as well as psychotic patients.35 Most antipsychotic
medications block the D2 receptor to prevent binding of the dopamine, resulting in
significant improvement in psychotic symptoms, but showing less improvement in the
negative symptoms. Thus, dopamine is most likely involved in schizophrenic symptoms,
but is not likely the main etiological factor.

1.1.5.2

Glutamate hypothesis

This thesis has focused on another excitatory neurotransmitter; glutamate. Although
glutamate is an essential excitatory neurotransmitter in vertebrates, it may be involved in
the symptoms of schizophrenia. In an animal study, Olney and Farber36 reported that
phencyclidine, a drug that inhibits the glutamate neurotransmission by blocking the Nmethyl D-aspartate (NMDA) glutamate receptor, could induce schizophrenic-like
changes. The rats that received phencyclidine demonstrated progressive loss of gray
matter in regions found to have similar changes in schizophrenia. Curiously patients who
ingest drugs that block NMDA receptors develop both positive and negative symptoms.37
Blockage of the NMDA receptor leads to impaired GABAergic activity, which inhibits
the glutamatergic neurotransmission. However when GABA activity is impaired there is
another pathway that is activated that leads to excessive glutamate neurotransmission
when the NMDA receptor is blocked.
This excessive glutamate neurotransmission can be toxic to neurons (excitotoxicity), and
may affect the glutamate pathways in the entire BGTC circuit. This toxic process
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eventually leads to the neuronal dysfunction, loss of synapses or neuronal death
(neurodegeneration). Thus we hypothesized that glutamatergic anomalies in
schizophrenia may lead to limited neurodegeneration associated with a loss of neuropil
and functional deficits. This theory could explain why schizophrenia symptoms such as
social withdrawal improved little and often persist throughout the lifetime of the patients.

1.1.6

Neurodevelopment versus Neurodegeneration

It is unclear at what time point schizophrenia is pathologically evident. Schizophrenic
symptoms typically appear around adolescence when a family member notices unusual
behavior or psychotic symptoms. This could coincide with cortical pruning, which may
uncover an early neurodevelopmental lesion. However, there is a debate over whether
schizophrenia is a neurodevelopmental or a neurodegenerative disorder. The former
theory indicates that there are abnormalities before-birth but that these are hidden or
hardly visible. These problems during gestation lead to a dealignment of the cortical
layers or abnormal cell migration as indicated above. This neurodevelopmental
hypothesis suggests that these anomalies do not progress after their manifestation during
adolescence.38 On the other hand, the neurodegenerative hypothesis suggests that there is
some sort of degenerating process after the development of psychiatric symptoms in
schizophrenia subjects.39 This theory has not been widely adopted due to a lack of
evidence of cell death in schizophrenia.40 For instance, a significant decrease in brain cell
number is found in several regions in Alzheimer’s disease patients, one of the
neurodegenerative disorders. Instead of evidence of cell death, loss of neuropil and
smaller neuronal size in schizophrenia are often reported. However, limited forms of
excitotoxicity not associated with cell death have been reported.41 Since deteriorating
social function is one of the clinical criteria in schizophrenia, we hypothesized that
schizophrenia may be a neurodegenerative disorder as well as a neurodevelopmental
disorder. To examine this hypothesis, we focused on the neurotransmitter glutamate,
which possibly leads to neuronal dysfunction. We have selected proton magnetic
resonance spectroscopy (MRS) to track the glutamatergic metabolites in schizophrenic
subjects in vivo.
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1.2 The Investigative Technique: Magnetic resonance
spectroscopy
Magnetic resonance imaging and spectroscopy are excellent techniques to measure
structural and neurochemical changes/differences in vivo as there is no ionizing radiation.
Thus, serial investigations are possible in both patients and healthy controls.

1.2.1

Principles of magnetic resonance imaging and spectroscopy

The research groups of Purcell42 and Bloch43 independently introduced the principle of
nuclear magnetic resonance (NMR) in 1946. They discovered that nucleus in strong
magnetic field, precess with a certain frequency (Larmor frequency). These precessing
nuclei could be made to interact with specific radio frequency energies and a nuclear
signal could be measured. The Nobel Prize in Physics 1952 was awarded jointly to Felix
Bloch and Edward Mills Purcell "for their development of new methods for nuclear
magnetic precision measurements and discoveries in connection therewith."
Building independently on this phenomenon the groups of Lauterbur44 and Mansfield45
are credited with the discovery of Magnetic Resonance Imaging (independent
publications in1973). The Nobel Prize in Physiology or Medicine 2003 was awarded
jointly to Paul C. Lauterbur and Sir Peter Mansfield "for their discoveries concerning
magnetic resonance imaging."

1.2.1.1

Net magnetization

Nuclear spins precess at the Larmor frequency (ω0), in a static magnetic field (B0). We
can write the ‘Larmor equation’ as; ω0 = γB0, where γ is the gyromagnetic ratio (2π ×
42.575 MHz/T for protons). Quantum mechanically, the only allowed orientation of these
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spins is either parallel or anti-parallel to the field, with the preferred direction being
parallel. In thermal equilibrium, a Boltzmann distribution can describe the ratio of
parallel to anti-parallel spins. For example at 1.5T and 37 Celsius, there is an excess of
only 1 in 100,000 spins that are parallel to the field. It is this spin excess that produces the
net magnetization (M0) parallel to B0 and ultimately contributes to nuclear signal which is
used to create an image. This net magnetization vector for most practical applications can
be treated in a semiclassical formalism, where the motion of the vector in the general
magnetic field is determined by the phenomenological Bloch equation:43
(1-1)
,
where Mz is the longitudinal magnetization, Mxy is the transverse component of the
magnetization, and T1 and T2 are the spin-lattice and spin-spin relaxation times
respectively. Bold font (e.g. M, B) refers to vectors.

1.2.1.2

M0 rotation along B1 and FID

Thus far, only a static magnetic field has been considered in the z direction. It is only
when the net magnetization vector is perturbed into the transverse (xy) plane that a signal
is detected in the receive coil, which is oriented in the xy plane. In order to direct the net
magnetization toward the x-y plane, a rotating magnetic field (B1) is often applied in the
x direction. This induces a precession of the net magnetization around the B1 vector, and
eventually into the x-y plane. To rotate in this manner, the frequency of B1 must be tuned
to the Larmor frequency. As the Larmor frequency is typically in the radio frequency
(RF) band, the B1 pulse is often referred to as an RF pulse. The rotation speed around B1
is slower with respect to the Larmor frequency because the B1 magnetic field (e.g. 10 µT)
is much smaller than the B0 field (e.g. 1.5T). When the RF pulse is turned off, the net
magnetization vector returns to thermal equilibrium (M0) oriented along the longitudinal
direction.
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1.2.1.3

FID, and T1 & T2 relaxation

The transverse component of this magnetization decreases as the spins lose their phase
coherence. This decrease in the net transverse component with precession at the Larmor
frequency is called free induction decay (FID). A FID is always generated when an RF
pulse is applied. While the longitudinal magnetization gradually recovers with time, the
transverse components of the spins gradually lose their phase coherence and the net
transverse magnetization decreases over time. These processes are due to T1 relaxation
and T2 relaxation, respectively. The re-growth process involves the energy exchange
between spins and the main kinetic energy of the nuclei through the dipole-dipole
interaction. A T1 process requires a magnetic field fluctuating near the Larmor
frequency. This oscillating magnetic field is generated by another proton or electron in
the same molecule or different molecule tumbling or moving with a frequency near the
Larmor frequency. T1 is the time that the longitudinal magnetization recovers from zero
to 63% of its equilibrium value after the end of the 90 degree RF pulse.
T2 is the decay time associated with the magnetization dephasing process in the
transverse plane. Phase coherence decreases quickly when the magnetic field fluctuation
induced by molecular motion or tumbling is much slower than the Larmor frequency. To
have an effect on the magnetization in the x-y plane these fluctuations must be along the
z axis. T2 is the time that the transverse component decreases to 37% after the RF pulse.
If the molecule tumbling rate or movement is much faster than the Larmor frequency, T2
in this environment becomes longer and eventually approaches T1. In this case, the static
dephasing originating in the local magnetic fields experienced by the spins is removed,
because the local magnetic fields are averaged due to “motional averaging.”

1.2.1.4

Selective excitation (slice selection), gradients

In order to rotate the net magnetization vector into the x-y plane, the magnetic field B1
must be maintained for a time, t, such that γ B1 t = π/2. This would tilt spins throughout
the entire volume through π/2, and is referred to as a 90 degree pulse. In order to rotate
the magnetization through 180 degrees, this same RF pulse could be applied, but
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maintained for a duration 2t. In order to excite a particular slice however, a linear
magnetic field gradient is required. This gradient creates a linear variation in the
magnetic field with respect to position, for example along the z-direction. With such a
linear gradient, the resonant frequency of the hydrogen nuclei varies depending upon
their physical location along the z-direction. While these gradients are active, the physical
slice of interest corresponds to a bandwidth of frequencies. In order to excite only those
spins corresponding to the physical slice, the RF pulse is typically shaped with a sinc
waveform such that a pulse with a particular frequency bandwidth can be generated. As
mentioned earlier, it is only when the net magnetization is directed into the x-y plane that
the FID is detected by the hardware. It is these signals that must be collected to form an
image.
The proton signals are received by a coil, the cross-sectional area of which is set
perpendicular to the transverse plane. This RF coil is often the equivalent of a coil of wire
tuned to the resonant frequency (the Larmor frequency). Often so called birdcage
resonators or birdcage coils are used in MRI, primarily for transmission of signal. A
complete description of these coils is beyond the scope of this thesis. However these coils
have good uniformity, and are cylindrical coils, placed in parallel with the main magnetic
field, and hence the bore of the MRI. These coils are a great advantage in MRI because
they can generate transverse magnetic fields while allowing a body to placed along the
cylindrical axis. For simplicity however, the signal detection will be considered to be
strictly from a simple solenoid.
Once the magnetic field is directed toward the transverse plane, it begins to precess
around the static field B0. Following a 90 degree pulse, the precessing magnetization
vector represents a rotating magnetic field that induces an oscillating signal in the RF
coil. This signal is the free induction decay. The decay of the magnetization is
characterized using the relaxation time T2*, which is composed of T2 and the magnetic
field inhomogeneity, which is determined by the magnetic field stability, quality of
shimming, and so on. T2* is often written as:
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(1-2)
,
where T2’ is the contribution to the decay due to magnet inhomogeneities, and other
susceptibility issues such as air-tissue interfaces, iron concentration, etc.

1.2.1.5

Fourier transform (time ↔ frequency)

Time and frequency, and similarly object space and spatial frequency are intimately
related through the Fourier Transform. The Fourier Transform, F(ω) of a function, f(t), is
given by:
(1-3)
,
and a similar relationship can be defined between a function in image space, f(x), and its
Fourier Transform in spatial frequency (or “Fourier”) space, F(kx). It turns out that the
MRI signal is related to the magnetization intensity through a Fourier transform. To
illustrate this relationship, it is instructive to first consider the process of phase and
frequency encoding in a simple spin echo MRI experiment.

1.2.1.6

Frequency-encoding & phase-encoding (MRI)

A simple spin echo (SE) experiment is illustrated in Figure 1-2. The Readout gradient, or
x-gradient, applied at the time of signal readout causes the resonant frequency (ω(x)) to
vary with x-position according to:
,

(1-4)

where ω0 is the Larmor frequency, γ is the gyromagnetic ratio, and Gx is the x- (readout)
gradient.
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Figure 1-2: MRI Sequence Diagram of a simple Spin-Echo
(Adapted from [46] )
This gradient is often referred to as the frequency encoding gradient. According to Figure
1-2, a phase, or y-gradient (Gy), is applied shortly after the initial 90 degree pulse;
however it is applied in a different manner than the x-gradient. Gy is applied for a fixed
time, ty, and the entire sequence is repeated a number of times, each with a different
gradient magnitude. During the time ty, the spins are given a different phase ωty,
depending upon their y position:
(1-5)
.
Each time the sequence is repeated with a different Gy, the spins are given a different
amount of phase encoding. This sequence is repeated N times, and an echo is recorded
with M points, generating a matrix (N × M) of echo's that differ by the amount of phase
encoding. When this block of data is 2D Inverse Fourier Transformed, the image
information is recovered. Rather than strictly imaging, MR spectroscopy isolates a signal
from a particular region in the volume. When this time varying proton signal is Fourier
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transformed, it now turns out to be a spectrum in the frequency domain. The full width at
half maximum of the spectrum is determined by (πT2*)-1.

1.2.1.7

Sampling rate, image resolution

Spatial frequency is the inverse (Fourier) space with respect to object space. The spatial
frequencies are defined in terms of the readout gradient amplitude, Gx, and the phase
encoding step, Gy, as:
(1-6)
,
(1-7)
.
Note that in order to sample the spatial frequencies, time, t, is varied to sample kx,
however the gradient amplitude, Gy, is varied to sample ky (ty is a constant). The simplest
definition of resolution is to divide the Field Of View (FOV) into Nx or Ny segments, so
that the resolution, δx and δy are given by:
(1-8)
.
Because position and spatial frequency form a Fourier pair, the width in object space
(FOV) is inversely related to the resolution in the frequency space (∆k):
(1-9)
.
By the same argument however, the extent or width in the frequency domain (Wkx and
Wky) should be related to the inverse of the resolution in the spatial domain. With the
assumption that the widths in the frequency domain are:
(1-10)
.
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Equations (1-8) through (1-10) show that δx = 1/Wkx and δy = 1/Wky as expected. Using
equations (1-6) and (1-7), expressions can be easily derived for ∆kx and ∆ky, the
sampling period:
(1-11)
,
(1-12)
,
where it is now explicit that increments in kx are related to increments in the digitizer
resolution (∆t), and increments in ky are related to increments in the phase encode
gradient (∆Gy). These expressions can then be used for a given pulse sequence to derive a
relationship between the pulse parameters and the FOV, resolution, and sampling rate.

1.2.1.8

Introduction of MRS physics, chemical shift

While MRI is composed primarily of the signals from the hydrogen nuclei of the water
molecules, magnetic resonance spectroscopy is closely related to the signals from the
hydrogen groups in the chemical structure of the sample or region. Frequencies of these
hydrogen groups are off-resonance from the Larmor frequency of water protons. One of
the primary contributors to this off-resonance is the chemical shielding, or chemical shift.
Because electrons on molecules can also become polarized in a magnetic field, the actual
field, and therefore the resonant frequency at the nucleus (ωeff) will be less due to this
chemical shielding (σ):
(1-13)
,
where σ is the isotropic chemical shielding. In a full quantum mechanical treatment, σ is
a tensor quantity. For a simple molecule that can be either parallel (σa) or antiparallel (σb)
to the field, the chemical shielding can be written in terms of an isotropic and an
anisotropic term:
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(1-14)
.
However in a liquid, the molecules will sample all orientations, and will average to zero
the anisotropic chemical shielding. The chemical shift, δ, in parts per million (ppm) is
defined as the shielding with respect to a reference, or equivalently, the shift in frequency
with respect to a reference:

(1-15)

,
where in brain proton MRS, the reference is usually chosen such that NAA = 2.01 ppm.
A phenomenon that generates a fine structure in the NMR spectrum is J-coupling. Jcoupling or indirect dipole-dipole coupling is an electronic nuclear interaction between
the electrons in a molecule and the hydrogen nucleus, which generates off-resonance
perturbations from the proton Larmor frequency. The degree of off-resonance effects
depends upon the chemical structure, and the organization of hydrogen nuclei in the
molecule. In addition, the spectral shape is no longer a single peak – this interaction
introduces a fine structure to the spectrum. The number of peak splittings is determined
by the hydrogen groups in the molecular neighborhood.
Because protons have a nuclear spin ½, they are restricted to either the spin up or the spin
down state. If a neighboring proton spin is exposed to this local field, then the spins of
the hydrogen nuclei will precess either faster or slower than the resonant frequency,
depending upon whether this proton neighbor is spin up or spin down. As a result, the
spectrum for this single proton is split into a pair of peaks called a doublet. Peaks can also
be split by multiple protons in a side group, and peaks can be split into doublets, triplets,
etc. This phenomenon is called J-coupling and the distance of the splitting is called the Jcoupling constant expressed in Hertz. It is mainly because of the chemical shift, and J-
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coupling, that the various metabolites can be identified based upon their unique spectral
signature.

1.2.2

Magnetic resonance spectroscopy

In general, there are two types of spectroscopy sequences, single and multiple voxel. A
single voxel sequence is composed of three RF pulses, each coincident with their own
slice selective gradient applied in each of the Cartesian axes. This process selects three
perpendicular slices, with the selected volume corresponding to the intersection of these
slices. The most common single voxel spectroscopy sequences are stimulated echo
acquisition mode (STEAM) and point-resolved spectroscopy (PRESS). Chemical shift
imaging (CSI) and magnetic resonance spectroscopic imaging (MRSI) are common
multi-voxel type sequences. While the data are collected from much larger regions
compared to single voxel spectroscopy, each volume tends to be bigger and the total data
acquisition time is much longer.

1.2.2.1

STEAM vs. PRESS sequences

Both STEAM and PRESS sequences are composed of three RF pulses. Each RF pulse
results in a free induction decay, each combination of two RF pulses produces a spinecho and three RF pulses create a stimulated echo as well as a double spin-echo. While a
stimulated echo is the primary signal to be detected in STEAM sequences, a double spinecho is the primary signal to be detected in PRESS sequences.
The STEAM sequence, depicted in Figure 1-3, is composed of three 90 degree RF pulses,
preceded by a CHEmical Shift Selective (CHESS) pulse. The RF pulses create one
stimulated echo (STE), three FIDs, three single spin-echoes, and one double spin-echo.
Because the stimulated echo is the only signal used, the other FIDs and spin-echoes are
spoiled using crushing gradients, dephasing their transverse magnetizations, so that they
do not contribute to the overall signal.
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Figure 1-3: STEAM Sequence Diagram
The black rectangles represent spoiling gradients. The gray rectangles represent
slice selective gradient with refocusing gradient. (Adapted from [47])
In theory, the signal completely recovers to the original amplitude in a PRESS sequence
while only half of the original signal is detected in the STEAM sequence. After the first
90 degree RF pulse in the STEAM sequence, the spins in the transverse plane (x-y plane)
dephase during the TE/2 period. For illustration, it can be assumed that the magnetization
is composed of 4 spins, their directions 90 degrees apart from each other on the
transverse plane after these spins dephase in the rotating frame of reference. The second
90 degree pulse flips these dephased spins to the y-z plane perpendicular to the transverse
plane. The two components on the y-axis dephase due to the crushing gradient during the
mixing time (TM) period. The third RF pulse rotates the spins along the longitudinal axis
onto the transverse x-y plane again. The MR signal is maximized at TE/2 after the last RF
pulse. However, the amplitude of this signal is a half of the original signals because the
other two transverse spins were dephased during the TM period.
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The PRESS sequence in Figure 1-4, on the other hand is composed of one 90 degree and
two 180 degree RF pulses. Unlike the STEAM sequence, the double spin-echo (DSE) is
the primary signal in the PRESS sequence.

Figure 1-4: PRESS Sequence Diagram
The black rectangles represent spoiling gradients. The gray rectangles represent
slice selective gradients. (Adapted from [47])
With a PRESS sequence, the dephasing spins are rephased at every TE/4 following a 180
degree pulse. Balanced gradients are implemented before and after the RF pulse. In
practice, the signal does not fully recover due to an imperfect slice profile, which is the
Fourier Transform of the RF pulse. A perfect slice profile is a rectangular shape, in which
all spins within the range are excited with the desired flip angle. The Fourier Transform
of a sinc function of infinite extent is a rectangular function. However, since the RF pulse
is implemented in a finite time, the slice profile is not a perfect rectangular shape, with
ringing artifacts at the edges of the slice profile.

20

Optimizing the slice profile of a 180 degree pulse is more difficult than designing the
slice profile of 90 degree pulses. In the worst case scenario, only a small portion of the
spins around the center of the slice profile rotate through 180 degrees but the others rotate
with different flip angles. Another disadvantage of the PRESS sequence is that metabolite
signals are sensitive to J-coupling, particularly at longer echo times. 180 degree RF
pulses induce spin flips in the neighboring protons and change the metabolite peak
shapes, a process called J-evolution.48 For example, the coupling constant between the
methyl protons and methine proton of lactate is approximately 6.9Hz. The doublet peak
representing the methyl group at 1.3ppm appears negative at 1/J (~144ms) and positive at
2/J (~288ms) using the PRESS sequence.

1.2.2.2

Quantification Methods

Spectral fitting is performed either in the time domain or in the frequency domain. Time
domain fitting, such as Singular Value Decomposition (SVD)49 or Hankel-Lanczos SVD
(HLSVD),50,51 is often used to subtract the remnant water resonances. Although these
methods are user-independent, they only seek the best mathematical combination of the
resonances, which does not take any biological meanings into account. Thus, SVD and
HLSVD are powerful techniques to subtract unnecessary resonances but these methods
are insufficient to perform an in vivo spectral fitting.
The linear combination model (LCModel) is the most common spectral fitting technique
in in vivo MRS.52 LCModel seeks the best compromise for the sum of these components
in the frequency domain using a model, composed of the metabolite peaks and their
concentration levels obtained from in vitro experiment. This type of model is referred to
as an “a priori knowledge” model. The detected MR signal is a summation of the
sinusoids with an exponential decay. With setting a range of the parameters, such as the
amplitude and phase of the damped sinusoids, a priori knowledge maintains a realistic
metabolite levels and their biological combination in the metabolite quantification.
Although LCModel is used in the frequency domain, the metabolite components in the a
priori knowledge are the Fourier Transformed time domain signals.
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Spectral fitting with a prior knowledge is also available in the time domain. The
algorithm seeks the minimum difference between the raw data and the model (i.e. the a
prior knowledge) in the time domain by adjusting the unconstrained parameters such as
the amplitude of the components. As described in “Spectral fitting” in the next section,
we have chosen to do the time domain fitting with the Levenberg-Marquardt algorithm.

1.2.2.3

Research Methodology

Since all relevant data were collected and processed in the same manner, the detailed
methodologies including data collection, pre-processing, spectral fitting and
quantification methods are described in this section.

1.2.2.3.1

Equipment, MRI and MRS sequences

All MR data were collected with a 4.0 Tesla Varian (Palo Alto, California,
USA)/Siemens (Erlangen, Germany) whole body scanner with a Varian Unity Inova
console and Siemens Sonata gradients, located at the Centre for Functional and Metabolic
Mapping of the Robarts Research Institute, London, Ontario, Canada. A transmit and
receive, circularly polarized birdcage head coil (XLR Imaging Inc., London, Ontario
Canada) was used throughout our studies. The volunteer’s head was placed inside of the
head coil and set at the center of the head coil aligned with the subject’s eyebrows.
Global shimming was manually performed with the first and second order shims to
reduce the magnetic field inhomogeneity.
A sagittal scout image was taken to plan the center of the transverse slices which cover
the entire head. The center slice passed through the genu of the corpus callosum and the
dorsal end of the splenium of the corpus callosum. Then, T1 weighted transverse images
were collected with a 3D MP-RAGE sequence which is a three-dimensional
magnetization prepared fast low angle shot (FLASH) sequence, flip angle = 30 degrees,
TR = 11.4 ms, TE = 6.2 ms, inversion time (TI) = 500 ms, matrix size = 256 × 256, field of

22

view = 20 × 20 cm2, resolution = 0.78 × 0.78 mm2, 64 contiguous slices of
thickness = 2.75 mm.
Using those T1-weighted images, the 10 × 15 × 10 mm3 (right-left, anterior-posterior,
inferior-superior direction) spectroscopy voxels were positioned in the left anterior
cingulate (Brodmann Area (BA) 32 & 24) and the left thalamus. MR spectroscopy data
were acquired with a single voxel STEAM sequence (TE = 20 ms, mixing time
(TM) = 30 ms, TR = 2000 ms, dwell time = 500µs, 8 step phase-cycling) with a chemical
shift selective pulse (CHESS) for water suppression. After the voxel localization, 90
degree RF pulse powers were optimized and local shimming was manually performed
with a water unsuppressed spectrum. The CHESS pulse, which was composed of three
Gaussian RF pulses, was turned on to optimize the RF power and pulse length.
Metabolite data were acquired with water suppression (256 averages), followed by the
water unsuppressed data (16 averages). This MRS procedure was conducted in the left
anterior cingulate and the left thalamus.

1.2.2.3.2

Pre-processing

Water suppressed data were corrected for eddy current and the spectrum line shape with
the QUality and Eddy Current Correction (QUECC) technique,53 which is a combination
of the “QUAntification improvement by converting LIneshapes to the Lorentzian TYpe”
QUALITY54 and “Eddy Current Corrections” (ECC), using the water reference spectrum.
QUALITY deconvolution was performed on the first 400 complex points (100ms) in the
time domain and ECC was performed on the rest of the complex points. Residual water
resonances (4.2 - 6.2 ppm) were subtracted using the HLSVD algorithm.51,55,56

1.2.2.3.3

Spectral fitting

Pre-processed data were fit using in-house software called Fitman56,57 (Lawson Health
Research Institute) to the first 1024 complex points (512ms) in the time domain. The
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fitting procedure was based on the Levenberg-Marquardt methods to minimize the
differences between raw data and the prior knowledge. Our model was created with the
twelve metabolites from in vitro measurement and eleven macromolecules from literature
values. 58,59 Each metabolite spectrum was composed of single Lorentzian peaks while
macromolecule spectra were Gaussian. Our template is composed of 247 single peaks
with six parameters; chemical shift, amplitude (signal intensity at t = 0), Lorentzian
linewidth, phase, delay time, and Gaussian linewidth. To reduce the time to find the
global minimum, all parameters except amplitude are constrained in our model.

1.2.2.3.4

Metabolite quantification and volumetric analyses

Metabolite concentration levels are quantified using the internal water reference.
Corresponding signal amplitudes are summed for each metabolite to express the peak
area. Metabolite concentration levels were calculated using the following formulae60:

,

(1-16)

,
(1-17)

where Area is the peak area of spectrum, Averages is the number of transients, Gain
represents the receiver gain, # of 1H is the number of proton nuclei in the molecule (i.e. #
of 1H water is 2), scaling factor is the scaling (e.g. 10-4) of the raw data, Water density 38C is
the density of water at human body temperature, and Water molecular weight 38C is the
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molecular weight of water at human body temperature. Metabolite peak area is divided
by the water peak area since water is set as the internal reference with the concentration
level 55.5556 [Mol / l ]. Water percentage is adjusted by the brain tissue fraction in the
spectroscopy voxel because of different water percentage in each brain tissue: 81% in the
gray matter (GM), 71% in the white matter (WM), and 100% in the cerebral spinal fluid
(CSF).61 There is an assumption that no metabolite exists in the CSF. The denominator
(1 - f CSF) is required to correct the water signal from the CSF. This adjustment is limited
for the small CSF fraction in the spectroscopy voxel.
The fraction of the brain tissue is calculated from each spectroscopy voxel (1.5 cm3) with
ANALYZE and in-house software called Xstatpack, developed by J Davis. The detailed
segmentation analysis is described in the Methods section in Chapter 3.
Volumetric changes in gray matter were measured with voxel-based morphometry
(VBM)62,63 on the T1-weighted anatomical images using Statistical Parametric Mapping
(SPM) (Wellcome Department of Imaging Neuroscience, University College London,
UK). Normalization was performed on all images with the T1-weighted template
developed by the Montreal Neurological Institute. Images were segmented into gray,
white and CSF compartments. Segmented images were then modulated using the
Jacobian determinants, created in the normalization step. Lastly, images were smoothed
with an isotropic Gaussian filter of 12mm full width at half maximum. A general linear
model with t-statistics was applied for the statistical comparisons.

1.2.3

Techniques and Disease: MRS findings in schizophrenia

Abnormal glutamatergic metabolite levels have been found in cross-sectional
schizophrenia studies using 1H MRS. Significantly elevated glutamine levels in the
anterior cingulate were found in never-treated schizophrenia patients64 and in patients at
high risk to develop psychosis.65 Tibbo et al. 66 reported a higher glutamate/glutamine
ratio in the right medial frontal lobe in patients at high generic risk compared to those at
low risk for schizophrenia. In the thalamus, Théberge et al.62 found an increased
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glutamine level in schizophrenia while Stone et al.65 reported a decreased glutamate level
in high-risk mental state patients. In the chronic studies, significantly decreased
glutamate and/or glutamine levels were found in the anterior cingulate.67-70 Théberge et
al.70 also reported a significantly increased glutamine level in the thalamus in chronic
schizophrenia patients.
One of the issues with 1H MRS measures of glutamate is that only 15-20% of the
glutamate MR signals are involved in the neurotransmission and the rest of the signals
come from the pooled glutamate in the vesicle,71 which does not have the same toxicity
as the glutamate released into the synaptic cleft. For this reason, the focus of this thesis
has been on measuring glutamine, a precursor of glutamate. Glutamate neurotransmitters
in the synaptic gap are taken up by the glial cells, converted to glutamine, synthesized
again to glutamate and pooled in the vesicle in the axon terminals. While 80% of the
glutamate MR signal comes from the pooled glutamate in the neurons, most of the
physiologically active glutamate comes from glutamine produced in glial cells.71
Therefore, glutamine may be a better indicator of the glutamate neurotransmission
although part of the pool of glutamate also arises from glucose via the tricarboxylic acid
cycle.72
Phosphorous magnetic resonance spectroscopy (31P MRS) allows the investigation of
neuronal damage, which may be caused by excitotoxicity. Phosphorous MRS is a useful
technique to observe the energy metabolism and cell membrane phospholipid
metabolism. Phosphocreatine (PCr) and inorganic phosphorous (iP) indicate the energy
metabolism. Phosphomonoesters (PME) and phosphodiesters (PDE) indicate the
phospholipid synthesis and membrane breakdown products. While significantly
decreased PME and increased PDE were found in the first episode studies,73,74 the
phospholipid membrane metabolism showed an increased, decreased or even normal
levels in chronic studies.75-77
Both 1H and 31P MRS findings are inconsistent in the chronic studies. This
inconsistency may be due to the variability in type and dose of medication used to treat
these patients. Longitudinal studies, however, are required to observe the disease process.
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Using 1H MRS, Théberge et al.60 examined seventeen never-treated schizophrenia
patients and completed their 30 month follow-up scans. It was reported that at the onset
there was an increased glutamine level in the patients compared to the healthy volunteers,
however those elevated glutamine levels were decreased in schizophrenia over the 30
month assessments. In a longitudinal 31P MRS study, Miller et al.78 reported an elevated
PME in first episode schizophrenia patients compared to controls, with a significantly
decreased PDE in schizophrenia patients at the 30 month assessment when compared
with their initial assessment.
These two longitudinal studies suggest a degenerative process in the first few years in
schizophrenia. However, several key questions are raised by these studies:

1. First, how long does this process persist in schizophrenia? Chapter 2 of this thesis is
an extension of the previous longitudinal study (Théberge et al.60) to investigate
whether these results persist out to 80 months.
2. Secondly, are metabolite levels such as glutamatergic metabolites and NAA affected
by structural changes in the brain? To address this question, the third chapter of this
thesis is designed to probe whether or not changes in the gray matter in the
spectroscopy voxel could be associated with observed changes in metabolite levels.
3. Lastly, it was noted from our long-term study that due to a hardware modification,
there was a change in the noise level of the system. Hardware replacements and/or
upgrades are inevitable, particularly as the duration of a study becomes longer.
Although our MR technician carefully maintained the MR system, with rigorous
quality control, this change in the system noise may have affected the metabolite
signal-to-noise ratio in our study. Thus the third and final question is: Did the signalto-noise ratio change due to this hardware modification, and was the metabolite
quantification affected? Chapter 4 represents a series of data manipulations and
simulations which were designed to answer this question.
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1.3 Hypotheses
1. Significantly higher glutamatergic metabolites during the first episode will decrease
in schizophrenia in a time course. Glutamatergic metabolite decreases will correlate
with widespread gray matter losses and social functioning at a 7 year follow-up
(Chapter 2).
2. Loss of glutamatergic metabolites in first episode patients over time will be related to
gray matter loss in the voxel of interest but will not be significantly affected by
signal-to-noise changes associated with gray matter loss. NAA levels will be less
likely to be affected by gray matter loss in the voxel of interest or signal-to-noise
changes (Chapter 3).
3. Significant differences in brain metabolites observed in our long-term study would
persist after the data manipulation to simulate a constant signal-to-noise ratio
throughout this study. Signal-to-noise ratio may be maintained in a reasonable range
during our long-term study (Chapter 4).

1.4 Overview of the thesis
This thesis is composed of two clinical studies (Chapters 2 and 3), and one technical
study (Chapter 4). Chapter 2 has been accepted, and the other two chapters (Chapter 3
and 4) will be submitted for publication.
Chapter 2 contains a long term follow-up schizophrenia study using in vivo proton
magnetic resonance spectroscopy. Eighty month follow-up scans were performed with
the same schizophrenia patients as in our 30 months study to see if the deterioration
persists in this disease. This manuscript has been accepted by British Journal of
Psychiatry.
Chapter 3 contains a study to examine the metabolite levels adjusted by the amount of
gray matter in the spectroscopy voxel. Significantly decreased metabolite levels and the
amount of gray matter were observed in the long term study, presented in Chapter 2. This
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analysis shows whether the loss of gray matter in the spectroscopy voxel is responsible
for the changes in the metabolite levels.
Chapter 4 contains a technical study to examine how the MR signal-to-noise ratio affects
the metabolite quantification. Metabolite signal-to-noise ratios tended to be higher in the
first two years of the 80 months follow-up study (Chapter 2). A possible explanation is
related to a hardware replacement, which is one of the potential confounding factors to
consider, particularly as the length of a longitudinal study grows. To assess this issue,
data manipulation in the corresponding data sets and noise simulation were performed to
see the influence of signal-to-noise ratio as well as the precision of the metabolite
quantification.
Chapter 5 is a summary chapter to discuss the entire results (Chapter 2 to 4) and future
work.
Appendix A contains preliminary work to compare mood disorder and schizophrenia
using the same methodology described in Chapter 2. These mental diseases are often
misdiagnosed due to an overlap in the clinical symptoms.
Appendix B describes the methodology used in this thesis.
Appendix C presents a sample spectrum.
Appendix D contains the ethics approval.
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Chapter 2

2

Gray matter and social functioning correlates of
glutamatergic metabolite loss in schizophrenia1

2.1 Introduction
The majority of structural neuroimaging studies in schizophrenia have found progressive
changes such as gray matter loss in subcortical regions.1 There has been considerable
controversy about what causes the progressive changes. Possible explanations include the
effects of medication,2 reduced neuropil3 and excitotoxicity induced by N-methyl-Daspartate glutamate receptor dysfunction.4 One of the proposed methods to investigate the
relative contribution of these factors is to combine volumetric analyses with functional
and neurochemical studies.1 Proton magnetic resonance spectroscopy (1H MRS) at high
field strengths allows examination of some aspects of excitotoxic processes by the
quantification of both glutamate and its precursor glutamine in a small volume of interest.
Very few studies have correlated longitudinal volumetric and neurochemical
measurements in schizophrenia.
We previously reported elevated glutamine levels in the left anterior cingulate and left
thalamus in never-treated first episode schizophrenia5 and decreased levels of glutamate
and glutamine in the left anterior cingulate of chronically-ill patients,6,7 which supports
the possibility of an excitotoxic process. However, these illness phase-related changes
may be confounded by age and medication effects. More recently, our group examined
longitudinal changes in glutamatergic metabolites and gray matter in first episode
schizophrenia over 30 months.8 Within the patient group, decreased thalamic glutamine
was found at 30 months compared to the baseline. Furthermore, a striking loss of gray
matter in widespread cortical regions such as dorsolateral prefrontal cortex and temporal
regions was found over 30 months in these patients. Gray matter loss in the superior

1
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temporal gyrus was significantly correlated with the loss of thalamic glutamine. The
correlation between gray matter and glutamine loss could indicate a degenerative process
but the study was limited by a relatively short follow-up period. If there is a degenerative
process in schizophrenia, it likely persists for several years.
The purpose of this study was to extend our glutamatergic and volumetric assessments to
seven years in first episode patients studied before treatment and after stabilization with
antipsychotics. We hypothesized that if there is a degenerative process in schizophrenia
patients, we would see a loss in not only glutamine but also glutamate and Nacetylaspartate (NAA), a marker of neuronal integrity9 in the anterior cingulate and the
thalamus. The glutamate-glutamine cycle accounts for 80-100% of total glutamate
trafficking in the brain.10 Thus glutamine may be an indicator of glutamatergic
signalling11 while loss of glutamate, glutamine, and NAA may suggest loss of synaptic
neuropil. We further hypothesized that the changes in these metabolites would correlate
with loss of gray matter, particularly in regions which might be expected to be involved
in schizophrenia such as the frontal and the temporal regions. If these changes in
glutamatergic metabolites reflect meaningful functional brain changes, we hypothesized
that we would see a correlation between changes in these metabolites and measurements
of social functioning despite treatment with medication.

2.2 Method
2.2.1

Participants

Seventeen patients diagnosed with schizophrenia participated in this study. The diagnosis
was established with the Structured Clinical Interview for DSM-IV12 by a psychiatrist
(P.W.). Ten of the patients were classified as paranoid type and seven patients were
classified as undifferentiated subtype. Patients were scanned three times: at their first
assessment in a never-treated state (NT), at 10 months, and at 80 months after their initial
examination. The MRS data at NT and 10 months from fourteen schizophrenia patients
have been reported in our previous study.8 Demographic information on participants is
shown in Table 2-1. Education levels, handedness and length of illness were rated as in
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our previous study.8 Symptoms were evaluated with the Scale for the Assessment of the
Negative Symptoms (SANS)13 and the Scale for the Assessment of the Positive
Symptoms (SAPS).14 Social functioning was evaluated with the Life Skills Profile rating
scale (LSPRS),15 composed of 39 items with a four-point response scale. This
questionnaire was completed by a family member living with each patient or a
caseworker through a phone interview within a few weeks after their latest assessment.
Seventeen matched healthy volunteers were recruited for the original study with an
advertisement distributed in London, Ontario. The controls were of comparable age,
gender, handedness, education level and parental education level. Healthy volunteers
were scanned twice (Con1, Con2); the mean interval between the two assessments was
approximately 43 months. Unfortunately, scanner replacement precluded longer followup in the control group. Subjects having a history of alcohol abuse and/or drug abuse in
the two years before the scan or head injuries were excluded. Nine healthy volunteers
participated in our previous study.8 The demographic data is displayed in Table 2-1. All
participants provided written informed consent according to the guidelines of the Review
Board for the Health Sciences Research Involving Human Subjects at the University of
Western Ontario.
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Table 2-1: Participants’ demographic information and data availability
Groups

Age, mean (s.d.), years
b
Gender
c
Handedness
d
Educational level ,
mean (s.d.)
Participants
Parents
e
Subtype
LOI, mean (s.d.), months
Symptom scale, mean
(s.d.)
SANS
SAPS
LSPRS, mean (s.d.)
Scan period, mean (s.d.),
months
f
Data availability
Anterior Cingulate, MRS
Thalamus, MRS
VBM

a

NT
(n = 17)
25(7)
14M/3F
12R/3L/2A

10 months
(n = 17)
25(8)
14M/3F
12R/3L/2A

80 months
(n = 17)
32(9)
14M/3F
12R/3L/2A

Con1
(n = 17)
29(10)
13M/4F
13R/4L

Con2
(n = 17)
32(10)
13M/4F
13R/4L

2(1)
3(1)
10P/7U
22(24)

2(1)
3(1)
10P/7U
33(27)

2(1)
3(1)
10P/7U
106(43)

3(1)
3(1)

3(1)
3(1)

44(12)
35(13)

33(11)
8(8)

33(12)
7(9)
128(18)

9(4)

84(31)

14X/1E/2M
12X/3E/2M
15X/2M

16X/1E
17X
17X

15X/2E
16X/1E
17X

43(14)
17X
17X
17X

17X
16X/1E
17X

LOI, length of illness; LSPRS, Life Skills Profile rating scale; MRS, magnetic resonance
spectroscopy; SANS, Scale for the assessment of negative symptoms; SAPS, Scale for
the Assessment of Positive Symptoms; VBM, voxel-based morphometry.
a. Groups: schizophrenia patients: NT, never-treated; 10 months, on medication for
approximately 10 months after their first scan; 80 months, approximately 80 months
medication after their initial assessment; controls: Con1, healthy volunteers comparable
age, gender and parental educational level with NT patients; Con2, follow-up scan for the
healthy volunteers in Con1 group.
b. M, male; F, female.
c. R, right-handed; L, left-handed; A, ambidextrous.
d. 1, grade 10 or below; 2, grade 11-13; 3, college 1-3 years; 4, college 4 years or more.
e. Subtype: P, paranoid; U, undifferentiated.
f. Data availability: X, available; E, excluded; M, missing.

Medication information is shown in Table 2-2. Five of the schizophrenia patients had
received antidepressant and/or benzodiazepines 1-10 days prior to their initial assessment
but had not taken any antipsychotic medication. Twelve of the patients had not received
any medication prior to their initial scan. All except one patient had been treated with
atypical antipsychotics at 10 months assessment. At the 80 months scan time, four of the
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patients were not taking any medication. Two patients had been treated with typical
antipsychotics while the remainder had been treated with atypical antipsychotics. For the
patients on antipsychotic treatment, chlorpromazine equivalent doses were calculated in
our previous study.8 In addition to the medication listed in Table 2-2, three patients had
been prescribed the following treatment: metformin in one tablet for diabetes, salbutamol
for asthma or tylenol for pain relief. None of the healthy volunteers, except one
participant who had taken a multivitamin daily, took any medication or supplements 24
hours prior to the date of scan.
Table 2-2: Medication: daily dosage

n
No medication
Antipsychotics
Haloperidol
Zuclopenthixol
Risperidone
Olanzapine
Quetiapine
Ziprasidone
Clozapine
Antidepressants
Paroxetine
Citalopram
Sertraline
Bupropion
Benzodiazepines
Clonazepam
Lorazepam
Zopiclone
Benztropine
CPZ eqa, mg/day

NT
(n=17)
Mean dosage,
mg (s.d.)

12

1
2

n
1

n

80 months
(n=17)
Mean dosage,
mg (s.d.)

4

1

1

5
3
3
2

3.7 (2.1)
7.5 (2.5)
300 (100)
100 (84.9)

2
1
3
3
3

1.3 (0.4)
6.4
3.3 (2.1)
26.7 (5.8)
317 (275)

2

300 (141)

1

100

30b
20 (0)b
1

1
3
1

10 months
(n=17)
Mean dosage,
mg (s.d.)

4b
2 (1.7)b
7.5b

NT, never-treated schizophrenia patients.
a. Chlorpromazine equivalent dose.
b. Taken 1-10 days prior to the scan.
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3

0.8 (0.3)

1
1

0.5
0.5

1

3
196 (146)

2

1.5 (0.7)
282 (285)
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2.2.2

Imaging and spectroscopy

Data were acquired with a 4.0 Tesla whole body MR scanner located at the Centre for
Functional and Metabolic Mapping of the Robarts Research Institute, London, Ontario,
Canada. A circularly polarized transmit/receive head coil was used. The MR system was
monitored by an MR technician, who performed weekly quality control with using the
phantom and with the echo planner imaging sequence. All data acquisition and
quantification procedures were performed as described in our previous study8: Imaging,
voxel positioning (left anterior cingulate and left thalamus (see Figure 2-1)), voxel size
(1.5 cm3), shimming, spectroscopy (STEAM sequence, echo time = 20 ms, mixing
time = 30 ms, repetition time = 2000 ms, dwell time = 500 µs), pre-processing, exclusion
criteria of MR spectrum, spectral fitting and metabolite quantification. Only metabolites
with a group coefficient of variation ((group standard deviation / group mean) × 100%)
less than 75% are reported: NAA, glutamate (Glu), glutamine (Gln), choline (Cho), total
creatine (tCr), myo-inositol (Myo) in the anterior cingulate and the thalamus; taurine
(Tau) and scyllo-inositol (Syl) in the thalamus only. The “total glutamatergic
metabolites” (tGL) refers to a sum of Glu and Gln levels quantified individually. A
complete description of MRI/MRS methods can be found in Appendix B.
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Figure 2-1: Voxel localization.
The white rectangles represent spectroscopy voxels in the left anterior cingulate and
the left thalamus. Localization was performed with transverse T1-weighted images,
in which the landmark of each region is seen. A, anterior; L, left; P, posterior; R,
right.

2.2.3

Statistical Analysis

All statistical analysis was performed with SPSS version 17.0 for Windows. Analysis of
variance (ANOVA) with a 2 × 2 split-plot factorial (SPF) design was conducted to
investigate the data composed of two repeated measurements in two independent groups
(NT and 80 months v. Con1 and Con2). The threshold was set at a two-tailed alpha of
0.05 for Glu, Gln, tGL and NAA, conservatively inasmuch as the a priori hypotheses of
their decrease over 80 months were unidirectional. A similar approach was used with a
separate analysis entailing the three repeated measures for the patient group; however, the
SPF design was replaced with a 3-level repeated measures (within-subject only,
randomized blocks) analysis (i.e. NT v. 10 months v. 80 months). An alpha of 0.05 was
retained when comparing NT v. 80 months, as used in our previous findings while alpha
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of 0.05 / 2 = 0.025 (two-tailed throughout) was applied for the two remaining pair-wise
comparisons (NT v. 10 months, 10 months v. 80 months). Huynh-Feldt epsilon was used
to adjust error-term degrees of freedom for repeated measures sphericity violations.
Regarding the other metabolites for which we did not have a priori hypotheses, a regionwise multivariate analysis of variance (MANOVA) using a 2 × 2 SPF design was applied
with an alpha of 0.05; a univariate ANOVA on each metabolite followed a significant
result of the multivariate level of analysis. Commensurate with our previous procedures,8
within-subject analyses for the patient group comprised pair-wise MANOVA’s, alpha
being set at 0.05 / 3 = 0.0167 (to accommodate non-orthogonality of these comparisons) at
both the multivariate and univariate levels, the latter analyses being contingent on
multivariate-level significance.
Correlation analyses were performed between metabolite levels of the schizophrenia
group and their demographic information, clinical scales (SANS/SAPS), social
functioning scale (LSPRS, 80 months only), length of illness and chlorpromazine
equivalent dose with the Pearson product-moment correlation coefficient. Threshold
alpha was set at 0.001 with the exception of the hypothesized relationship between
metabolites and LSPRS.

2.2.4

Voxel-based morphometry

Gray matter volume changes were measured with voxel-based morphometry (VBM)16,17
on the 3D T1-weighted anatomical images using SPM2 (Wellcome Department of
Imaging Neuroscience, University College London, UK) after normalization as described
in the section 1.2.2.3.4 in this thesis or elsewhere.8 The general linear model with tstatistics was applied for statistical comparisons; unpaired t-tests were used for betweensubject comparisons (Con1 v. NT, Con2 v. 80 months), and paired t-tests were used for
repeated measures, within-subject comparisons (NT v. 10 months v. 80 months, threelevel; Con1 v. Con2). The threshold for each test within each set of tests was established
according to a multiple-comparison False Discovery Rate (FDR) corrected alpha of 0.001
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with the extent threshold (cluster size k = 5). Correlation analysis between gray matter
changes and two of the metabolites, glutamine and NAA, was performed with a test-wise
alpha of 0.001.8

2.3 Results
No significant change in the signal-to-noise ratio was detected in the weekly quality
control throughout the entire study. A total of 168 MRS data (2 regions × (17 patients × 3
time points + 17 controls × 2 time points) - 2 missing data at 10 months assessment) were
collected for this study. Nine of these spectra were excluded due to voluntary or
involuntary movement such as excessive movement or breathing-related movement
during the data acquisition. Glutamate and glutamine levels in the anterior cingulate from
one schizophrenia patient were excluded because the raw data for this participant at 80
months did not fit a glutamate and glutamine peak in this instance. Because of the nonphysical values for glutamate and glutamine for this case, they were excluded. However,
for this individual the other metabolites were well resolved, therefore it was decided to
include them in the statistical analysis. MRS results are shown in the Figure 2-2 with the
error bar representing the standard deviation of each group. As indicated in Figures 2-2,
we were not able to follow-up all subjects for technical and/or clinical reasons. Voxelbased morphometry data were analyzed from 83 anatomical volumes (17 patients × 3
time points - 2 missing time points + 17 controls × 2 time points) as shown in Table 2-1.
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Figure 2-2: Metabolite levels.
Metabolite levels measured in the left anterior cingulate and the left thalamus from
healthy volunteers (Con1, Con2) and schizophrenia patients (NT, 10 mo and 80 mo). a,
NT & 80 mo higher than Con1 & Con2, 2×
×2 SPF analysis in group effect; b, Significant
reduction from Con1 to Con2 in two-tailed paired t-test; c, 2×
×2 SPF analysis in
group×
×time interaction; d, Significant reduction from 10 mo to 80 mo in two-tailed
paired t-test; e, Significantly higher level in NT than in Con1 in two-tailed unpaired ttest; f, Con2 & 80 mo higher than Con1 & NT, 2×
×2 SPF analysis in time effect; g,
Significant reduction from 10 mo to 80 mo in two-tailed paired t-test. Cho, choline;
Con1, healthy volunteers at the initial assessment; Con2, follow-up examination for the
healthy volunteers; Gln, glutamine; Glu, glutamate; NAA, N-acetylaspartate; NT,
never-treated; Myo, myo-inositol; Syl, scyllo-inositol; Tau, taurine; tCr, total creatine;
tGL, sum of glutamate and glutamine; 10 mo, 10 months assessment; 80 mo, 80 months
assessment.
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2.3.1

Between-subject comparison

A 2 × 2 univariate SPF ANOVA on anterior cingulate glutamine yielded a significant
group effect only (F = 5.04, d.f. = 1,28, P = 0.033). Note that this analysis was applied to
30 data sets (13 patients and 17 controls) for which glutamate and glutamine were
available at both time points. Analyses of NAA, glutamate and tGL levels yielded no
statistically significant results. Multivariate and univariate tests did not evince significant
effects for any other metabolite. In the thalamus, the univariate 2 × 2 SPF analysis did not
reveal any group effect for NAA, glutamate, glutamine and tGL. For comparisons at the
individual time points, the glutamine level of the NT group was significantly higher than
that of Con1 group (t = 2.72, d.f. = 1,31, P = 0.011) as presented in Figure 2-2. Neither
multivariate nor univariate tests revealed significant group effects in the other
metabolites.
No significant gray matter difference between groups was observed at each time point at
the FDR alpha of 0.001. Gray matter differences were only seen at an uncorrected alpha
of 0.001; Con1 gray matter volume was greater than in the NT group in the left thalamus
(x y z, -20 -24 10, pulvinar, t = 3.71, d.f. = 1,32), Con2 gray matter volume was greater
than the 80 month group in the left sub-lobar (x y z, -16 28 0, caudate body, t = 4.02,
d.f. = 1,32) and left superior temporal gyrus (x y z, -66 -8 2, BA 22, t = 3.87, d.f. = 1,32).

2.3.2

Within-subject comparison (three-level)

Region-wise univariate three-level repeated measures analyses yielded no significant
findings for NAA, glutamate, glutamine and tGL. Multivariate repeated measures in the
other metabolites did not yield statistical significance in either the anterior cingulate
(P = 0.083) or the thalamus (P = 0.034 > 0.0167).
Among the schizophrenia patients, gray matter in the left anterior cingulate (x y z, -1 53
2, BA 24 and 32, t = 6.08, d.f. = 1,28) and the left thalamus (x y z, -12 -2 -2, t = 4.52,
d.f. = 1,28) significantly diminished from the never-treated to 80 months assessment.
Figure 2-3 represents gray matter loss over 80 months. Significant decrease occurred with
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respect to the cross-sectional images of the T1-weighted template, centred at the left
thalamus. Significant loss was also observed in the frontal (BA 4, 10, 45 and 46),
temporal (BA 21), parietal (BA 7), occipital (BA 18 and 30), limbic lobes (BA 24 and
30) and sub-lobar (putamen) regions. Significant gray matter loss from 10 months to
80 months assessment was seen in the frontal lobe (BA 4, 6 and 9). All coordinates are
listed in Table 2-3. No gray matter loss was observed in 10 months as compared to NT.

Figure 2-3: Gray matter loss in schizophrenia over 80 months.
Gray matter loss from never-treated state to 80 months assessment in schizophrenia
patients with 3-level repeated measures (false discovery rate corrected P < 0.001).
Significant reductions represented as shaded region are super imposed on to the
cross-sectional T1-weighted template images. The bar at the bottom right represents
the t-value. The cursor in the images was placed in the left thalamus (x y z, -12 -2 -2,
MNI coordinate). This area showing the significant gray matter loss was indicated
in the white line.
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Table 2-3: Voxel-based morphometry: significant gray matter loss with the 3-level
repeated measures in schizophrenia patients
x

y

z

R/L

Lobe

NT

> 80 mo

Cluster
a
k
=1,28)

Voxel
t

(k=5, corrected p

BA/substructure
<0.001, d.f.

Gyrus

58

26

24

R

Frontal

Inferior frontal

45

61942

10.86

54

30

32

R

Frontal

Middle frontal

46

61942

10.78

-26

62

4

L

Frontal

Superior frontal

10

61

4.69

-50

-14

60

L

Frontal

Precentral

4

61942

10.86

-56

-4

-24

L

Temporal

Middle temporal

21

146

4.79

-12

-62

36

L

Parietal

Precuneus

7

991

6.11

18

-62

30

R

Occipital

Precuneus

30

873

5.65

-12

-86

22

L

Occipital

Cuneus

18

32

4.74

14

-2

34

R

Limbic

Cingulate

24

1281

6.14

16

10

32

R

Limbic

Cingulate

24

1281

5.40

-18

-60

16

L

Limbic

Posterior cingulate

30

991

5.43

22

-56

14

R

Limbic

Posterior cingulate

30

873

5.35

-1

53

2

L

Limbic

Anterior cingulate

24, 32

61492

6.08

12

54

10

R

Limbic

Anterior cingulate

24, 32

64492

6.89

18

6

2

R

Sub-lobar

Lentiform

275

5.42

-12

-2

-2

L

Sub-lobar

Thalamus

49

4.52

10

mo

(k=5, corrected p

Putamen
Ventral
anterior
<0.001, d.f.

> 80 mo

=1,28)

28

50

40

R

Frontal

Superior frontal

9

17

6.27

-46

6

58

L

Frontal

Middle frontal

6

5

6.10

50

-14

62

R

Frontal

Precentral

4

14

5.94

(k=5, FDR corrected P<0.001, d.f.=1,28)
NT, Never-treated; 10 mo, 10 months assessment; 80 mo, 80 months assessment; BA,
Brodmann area; FDR, False discovery rate; L, left; R, right.
a. Cluster size (voxels).

2.3.3

Within-subject comparison (two-level)

Within the univariate 2 × 2 SPF layout, no significant time effect or group × time
interaction was found in NAA, glutamate, glutamine and tGL in the anterior cingulate. In
a paired comparison, a trend toward decreased in NAA level from 10 months to 80
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months was found (t = 2.44, d.f. = 1,12, P = 0.031 > 0.025). The MANOVA on the
remaining metabolites yielded no statistically significant results. A significant univariate
group × time interaction was found for myo-inositol (F = 5.01, d.f. = 1,29, P = 0.033),
resulting from a significant decrease over time in controls (t = 2.51, d.f. = 1,16, P = 0.023).
In the absence of statistical significance at the multivariate level of analysis, like the nonsignificant univariate-analysis trend, above, this local result should be considered with
caution. It nevertheless is reported for possible future consideration.
Thalamic NAA, glutamate, glutamine and tGL did not show significant effects with
respect to either time or group × time sources in the univariate 2 × 2 SPF analysis. There
was a trend toward a decreased glutamine level at 80 months compared to the NT
measure (t = 1.82, d.f. = 1,15, P = 0.089) while tGL significantly decreased from NT to 80
months (t = 2.20, d.f. = 1,15, P = 0.044). An example of glutamate and glutamine
components as well as the fit spectra is presented in Appendix C. Thalamic NAA of the
schizophrenia group at 80 months significantly decreased from measured levels at 10
months (t = 2.97, d.f. = 1,11, P = 0.013). The 2 × 2 SPF MANOVA revealed a significant
time effect in the remaining metabolites (F = 2.84, d.f. = 5,26, P = 0.035). The significant
multivariate effect was paralleled by a significant univariate time effect for choline
(F = 4.19, d.f. = 1,30, P = 0.049). There was a trend to increasing choline level at 80
months compared to NT (t = 1.87, d.f. = 1,15, P = 0.080) but no significant change was
observed between Con1 and Con2. No significant gray matter loss was found in controls
between their two scans (Con1 v. Con2).

2.3.4

Correlations

Correlation between gray matter reduction and loss of thalamic glutamine over 80 months
was found in the ventral regions such as the right temporal pole (x y z, 16 14 -34, BA 38,
r = 0.884, P < 0.001), presented in Figure 2-4. The detailed area is listed in Table 2-4.
NAA reduction over 80 months in the left anterior cingulate correlated with the gray
matter loss in the posterior regions, listed in Table 2-5.18 Figure 2-5 represents the
correlation between NAA loss and gray matter reduction in the right inferior parietal

50

lobule (x y z, 62 40 28, BA 40, r = 0.841, P < 0.001). The correlation between the losses
of gray matter and either glutamine in the anterior cingulate, NAA in the thalamus, or
tGL in both regions did not reach the P < 0.001 level. Among the changes in metabolites,
the losses in NAA and tGL levels from 10 months to 80 months tended to be positively
correlated in the anterior cingulate (r = 0.625, P = 0.025, N = 13).

Figure 2-4: Correlation between gray matter loss and glutamine reduction.
Gray matter loss in the right temporal pole (x y z, 16 14 -34, BA 38) was
significantly correlated with the reduction of thalamic glutamine from never-treated
to 80 months assessment in schizophrenia.
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Table 2-4: Voxel-based morphometry: positive correlation between gray matter loss
and glutamine loss in the left thalamus from NT to 80 months

493

Voxel
t
5.96

11

493

5.11

Middle frontal

47

199

5.35

Frontal

Middle frontal

47

11

4.26

R

Frontal

Inferior frontal

47

199

5.06

-14

L

Frontal

Subcallosal

47

51

4.62

14

-34

R

Temporal

Superior temporal

38

529

7.09

-70

-34

-18

L

Temporal

Middle temporal

21

676

4.97

40

-34

0

R

Temporal

Sub gyral

-

5

4.01

-30

-64

34

R

Parietal

Angular

39

13

4.08

-12

6

-34

L

Limbic

Uncus

28

370

5.07

x

y

z

R/L

Lobe

Gyrus

-10

66

-12

L

Frontal

Superior frontal

BA/substructure
11

6

68

-14

R

Frontal

Superior frontal

42

34

-4

R

Frontal

-44

34

-4

L

30

32

-2

-14

16

16

(k=5, uncorrected P<0.001, d.f.=1,14)
NT, Never-treated patients; BA, Brodmann area; L, left; R, right.
a. Cluster size (number of voxels).

Voxel k

a
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Figure 2-5: Correlation between gray matter loss and NAA.
Gray matter loss in the right inferior parietal lobule (x y z, 62 40 28, BA 40) was
significantly correlated with the reduction of NAA in the left anterior cingulate from
never-treated to 80 months assessment in schizophrenia.
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Table 2-5: Voxel-based morphometry: positive correlation between gray matter loss
and NAA loss in the left anterior cingulate from NT to 80 months

7

Voxel
t
4.52

9

287

7.15

Inferior frontal

46

148

6.14

Frontal

Inferior frontal

46

148

4.56

R

Frontal

Middle frontal

6

27

4.55

46

R

Frontal

Precentral

4

287

5.58

-64

54

L

Parietal

Superior parietal

7

1720

8.48

-30

-56

68

L

Parietal

Superior parietal

7

1720

7.87

16

-74

62

R

Parietal

Superior parietal

7

752

5.65

54

-40

52

R

Parietal

Inferior parietal

40

142

6.86

62

-40

28

R

Parietal

Inferior parietal

40

122

5.39

54

-48

50

R

Parietal

Inferior parietal

40

142

4.95

66

-36

38

R

Parietal

Inferior parietal

40

122

4.33

46

-68

46

R

Parietal

Inferior parietal

40

5

4.13

-50

-74

-34

L

Parietal

Angular

39

1720

7.24

16

-58

74

R

Parietal

Postcentral

7

752

7.47

56

-16

48

R

Parietal

Postcentral

3

287

5.09

-10

-68

40

L

Parietal

Precuneus

7

30

5.05

-18

-66

26

L

Parietal

Precuneus

7

30

4.57

-10

-74

48

L

Parietal

Precuneus

7

30

4.31

-12

-62

22

L

Parietal

Precuneus

31

30

3.96

22

-62

22

R

Occipital

Precuneus

31

285

6.55

12

-62

26

R

Occipital

Precuneus

31

285

4395

-18

84

-2

L

Occipital

Lingual

17

230

6.04

28

-66

0

R

Occipital

Lingual

19

285

5.47

20

-96

14

R

Occipital

Cuneus

18

14

4.76

x

y

z

R/L

Lobe

Gyrus

-32

22

58

L

Frontal

Superior frontal

BA/substructure
8

56

8

34

R

Frontal

Inferior frontal

56

42

4

R

Frontal

62

52

2

R

36

16

60

56

-8

-44

Voxel k

a

(k=5, uncorrected P<0.001, d.f.=1,12)
NT, Never-treated patients; BA, Brodmann area; L, left; R, right.
a. Cluster size (number of voxels).

No correlation between loss of thalamic glutamine level and gray matter reduction was
found between two measurements in controls. The only significant correlation between
anterior cingulate NAA reduction with gray matter loss in controls was found in a small
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cluster (voxel k = 5) in the middle frontal gyrus (x y z, 28 -14 64, BA 6, r = 0.736,
P < 0.001).
LSPRS evaluated at 80 months was negatively correlated with the loss of thalamic tGL
from NT to 80 months (r = 0.694, P = 0.003) (Figure 2-6). Significant correlation between
chlorpromazine equivalent dose at 80 months assessment and gray matter loss from
never-treated to 80 months was found in bilateral sub-gyral (x y z, -50 -44 -12, BA 37,
r = 0.710 ; x y z, 48 -42 -8, BA 37, r = 0.704 ) in the temporal lobe at P < 0.001 level. No
other correlations were found in the other metabolite levels with SANS/SAPS scores,
length of illness, the LSPRS and chlorpromazine equivalent dosage.

Figure 2-6: Negative correlation between LSP and tGL loss
Life skills profile rating scale at 80 months assessment was negatively correlated
with the total glutamatergic metabolites (tGL) in the thalamus from never-treated
to 80 months assessment in schizophrenia
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2.4 Discussion
2.4.1

Neurochemical Alterations

Glutamine levels in never-treated patients were significantly higher than controls in the
left thalamus in keeping with the previous reports5,8 while levels in the anterior cingulate
were not significantly different between groups possibly due to higher standard
deviations in the control samples. No differences were seen between never-treated
patients and patients stabilized on medications suggesting that neuroleptic medication did
not affect glutamatergic metabolite levels.
Although we did not see a significant reduction in thalamic glutamine level over 80
months in schizophrenia, there was a significant decrease in the total glutamatergic
metabolites (tGL), suggesting glutamatergic metabolism continues to decline with disease
progression. This glutamatergic loss in the thalamus could also suggest a loss of neuropil
in schizophrenia. This observation is consistent with the suggestion that excitotoxicity
occurs primarily in the early stages of illness.19 However it is also possible that
glutamatergic findings could be accounted for by alterations in the activity and density of
glutamate dehydrogenase and glutamine synthetase which have been reported to be
anomalous in post-mortem schizophrenic brain extracts.20 The thalamic tGL reduction
was inversely correlated with the LSPRS, suggesting a connection between glutamatergic
neurophysiological changes and the impairment of social behavior. It is of note that this
correlation was found despite treatment with antipsychotic medications. Therefore, this
finding indicates that the change in glutamatergic metabolites may be a potential
indicator of severity in schizophrenia in terms of social functioning.
Indeed, Tibbo et al.21 reported a correlation between Glu/Gln ratio in the frontal cortex in
adolescents at high-risk for schizophrenia and Global Assessment of Functioning Scale,
suggesting the glutamatergic changes are a candidate marker in the early stage of
schizophrenia. Wood et al.22 reported a strong correlation between NAA/Cr ratio in the
middle frontal gyrus in the patients with psychosis and the Social Functional Assessment
Scale at 18 months follow-up. Although there are several differences such as the
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metabolite and its region compared to this study, they also suggest a connection between
metabolites and functional outcome.
In addition to the glutamatergic findings, a trend in the reduction in the levels of NAA
was found in the left anterior cingulate (P = 0.031 > 0.025) and a reduction was found the
left thalamus (P = 0.013) between the 10 months stabilized on medication and the 80
months assessment. These NAA deficits were not found to differ in a 30 month study.8
As NAA levels are generally thought to reflect neuronal integrity, this decline would be
consistent with decreasing glutamatergic metabolite levels and possibly a loss of neuropil
or limited apoptosis. Indeed, NAA and tGL reductions from 10 months to 80 months
assessment tended to be positively correlated in the anterior cingulate suggesting that
both metabolites may be related to neuropil loss. However, medication effects are also a
possibility as NAA levels in never-treated patients were not statistically different from
the same patients at 80 months follow-up.
No differences in glutamate, glutamine, tGL and NAA were seen in controls between
baseline and follow-up scans. Those findings were consistent with the measurement at 30
months.8 However, controls in this study were not followed as long as patients due to
decommissioning of the MRI system. This study had been running over 12 years on the
same MRI scanner. Compared at the latest assessment, glutamate and glutamine levels in
schizophrenia were not significantly different from those in controls. Decreased levels of
both metabolites have been reported in the anterior cingulate in chronic patients who had
been ill in excess of 20 years.6 The lack of differences at 80 months between controls and
patients implies that metabolite levels change more slowly over a considerable length of
time.

2.4.2

Volumetric Alterations

There was no significant difference between never-treated schizophrenia patients and
controls with FDR corrected P < 0.001 level while some gray matter losses were observed
with the uncorrected P < 0.001 level in the thalamus, where significantly higher glutamine
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level was found in schizophrenia. However, these differences were not to the extent
expected if schizophrenic symptoms were due to a programmed loss of neuropil.3
Significant gray matter loss in schizophrenia patients over 80 months was observed in
many brain regions including the anterior cingulate and the thalamus. This result suggests
that it takes 7 years until gray matter losses are observable in many regions. Indeed, no
reduction in the anterior cingulate and the thalamus was found during the 30 months
assessment in our previous report.8 A gray matter reduction was also found in the frontal
lobe in the 80 months compared to never-treated assessment and to the 10 months
assessment, highlighting the importance of the frontal lobe in schizophrenia. There was
no significant gray matter loss from never-treated to 10 months assessment, suggesting
that the acute effects of medication are minimal. Significant correlations between gray
matter loss over 80 months and chlorpromazine equivalent dose were found only in the
sub-gyral in temporal lobe bilaterally suggesting that medication is not likely the
explanation for the widespread gray matter losses seen in these patients.
There was no significant gray matter loss in controls between the two assessments,
implying aging effects are minimal. However, the mean scan period of controls was
around 3.5 years, shorter than the patients’ scan period. No significant gray matter
difference (FDR corrected P < 0.001) was found in Con2 compared to 80 months. There
were differences in the left superior temporal gyrus and caudate nucleus, albeit by more
liberal criteria (uncorrected P < 0.001), but which nevertheless are consistent with both
our earlier study8 and with another study.23

2.4.3

Correlations between Gray Matter and Metabolite Losses at
80 months

The amount of thalamic glutamine in schizophrenia patients was significantly correlated
with gray matter volume in the middle and inferior frontal gyrus as well as in the
temporal pole. A similar correlation between thalamic glutamate and gray matter loss in
these regions was reported in subjects at risk of developing schizophrenia.24 Several
prefrontal regions and temporal pole are associated with social and emotional processing
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which may be deficient in schizophrenia patients.25,26 As discussed in the previous
section, social functioning on the LSPRS was negatively correlated with tGL loss in the
thalamus in patients, suggesting this correlation is mediated in part by these widespread
structural changes. No correlations were found between losses of thalamic glutamine and
gray matter in controls, suggesting that aging did not play a significant role.
The reduction of NAA in the anterior cingulate was significantly correlated with the gray
matter loss over 80 months in posterior-parietal areas. This area is associated with
attention which many investigators have found to be altered in schizophrenia.27 These
regions are also interconnected and form part of the default network associated with selfmonitoring. Aberrant connectivity between the anterior portions of this network and other
regions in schizophrenia patients has been reported by our group and others.28-30
Localized changes in these networks reflected by metabolic measures could lead to
difficulties in self-monitoring which may underlie many symptoms of schizophrenia.29 In
contrast to multiple locations in schizophrenia, reduction in the anterior cingulate NAA
levels in controls was only correlated with gray matter loss in the motor area. This cluster
size was equal to the extent threshold, suggesting minimal correlation between neuronal
integrity and neuropil in normal aging.

2.4.4

Excitotoxicity or Plasticity

Although metabolite reductions, gray matter loss and their correlations over 80 months
may suggest a neurodegenerative process in schizophrenia, there has been a debate about
whether these anomalies are caused by excitotoxicity or plasticity. In contrast to our
previous report,8 here, a loss of glutamatergic metabolites was observed in the thalamus
concurrently to gray matter loss within the spectroscopic voxels (i.e. the anterior
cingulate and the thalamus). If there is an excitotoxic process in schizophrenia,
significant loss of gray matter in the thalamus might be expected in patients compared to
controls at their initial assessment. However, there was no significant difference between
these groups, suggesting the glutamatergic metabolite changes may be more sensitive to
early changes not associated with gray matter loss.
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Thalamic glutamatergic neurons are interconnected to all the cortical regions which were
associated with gray matter loss in the schizophrenia patients. They also form part of the
basal ganglia-thalamocortical neuronal circuit implicated in the pathophysiology of
schizophrenia.31 Thus glutamatergic changes in the thalamus could be associated with
glutamatergic changes throughout the cortex. Cortical gray matter losses could be
accounted for by excitotoxicity into these regions. Increased membrane breakdown has
been reported in first episode schizophrenia patients in a phosphorus MRS study.32 The
decrease in NAA and decrease in gray matter over time in the anterior cingulate in this
study would be compatible with this explanation. The trend to increased thalamic choline
levels in patients at 80 months may also suggest excitotoxicity as these levels reflect
mostly membrane metabolites. A positive correlation between choline and the duration of
untreated psychosis has been found in first episode patients.33 However, it is possible that
these circuits are simply being down-regulated leading to plastic changes in gray matter
and the metabolic changes.

2.4.5

Limitations

Although the absence of differences in metabolites and gray matter between the nevertreated and 10 month assessments in patients argues against medication effects, the
effects of exposure to medication can never completely be eliminated due to ethical
considerations. Another limitation may be the stability of the MR scanner associated with
the inevitable hardware replacements and/or upgrades that occur during such a long-term
period but the stability of our MR system was carefully monitored through routine
weekly quality control. We did not regularly calibrate the metabolite quantification.
However, the metabolite levels were quantified with the internal water reference which
minimizes short- and long-term scanner drift. Due to scanner replacement, we were
unable to follow controls as long as patients. Consequently we cannot exclude the
possibility that controls may have had further NAA losses had we followed them longer.
The lack of obvious changes in tGL between the two assessments in controls suggest that
aging alone would be unlikely to account for changes seen in patients at the 80 month
assessment.
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Chapter 3

3

Gray matter vs. metabolite signal to noise ratio

3.1 Introduction
Advances in neurochemical and structural imaging have contributed much to the
understanding of neuropsychiatric diseases such as Alzheimer’s disease and
schizophrenia.1 Since these illnesses are progressive, they are possibly neurodegenerative
disorders.2,3 Decreases in N-acetylaspartate (NAA) level, an indicator of neuronal
integrity and neuropil volume, have been reported in longitudinal studies of both
conditions.4,5 Glutamate is another possible marker of neurodegeneration because of
excitotoxicity associated with the excessive release of this neurotransmitter in conditions
like schizophrenia.6 However, findings are inconsistent in terms of the pattern of brain
changes. Therefore, it has been suggested that volumetric measurements should be
combined with metabolite changes.7
Magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H
MRS) are used to measure volumetric and neurochemical abnormalities in the human
brain, respectively. In the past three decades, anomalies in brain tissue and in metabolite
levels in schizophrenia have been reported with these techniques. Our group found
increased levels of glutamine in the anterior cingulate and the thalamus in schizophrenia
patients before treatment compared to a control group using MRS.8 Théberge et al.8 also
reported correlated losses of thalamic glutamine and gray matter in those patients over a
30 month period.9 We recently found longitudinal decreases in the levels of NAA and
total glutamatergic metabolites in the thalamus in the same schizophrenia patients after
80 months.10
It was unclear if our findings represented actual or apparent decreases in metabolite
levels due to the gray matter loss in the spectroscopy voxel. These quantified metabolite
levels were normalized with an arbitrary correction factor, composed of gray matter,
white matter and cerebrospinal fluid (CSF) percentage in the spectroscopy voxel.
However, we did not correlate the raw metabolite MR signal with the actual amount of

64

gray matter in the voxel to determine if they were related. If gray matter changes
correlate highly with glutamatergic metabolite changes then glutamatergic changes may
reflect a loss of neuropil rather than physiologically-relevant concentration changes in
this neurotransmitter. We also did not examine the effects of losses in gray matter in the
voxel on signal-to-noise ratio (SNR) which may have affected the precision of the
metabolite determination.
Long term longitudinal studies of neuropsychiatric disorders are becoming increasingly
common. However, to our knowledge no studies have examined the effects of gray
matter loss on the precision of measurements of relevant brain metabolites over time. The
purpose of this study was to examine the effects of gray matter loss on the measurement
of NAA and glutamatergic metabolites over 80 months in a group of schizophrenic
patients and controls. We hypothesize that gray matter losses alone would not account for
longitudinal changes in glutamatergic metabolites but that losses of gray matter may
affect SNR making it more difficult to detect changes over time.

3.2 Methods
3.2.1

MR imaging and spectroscopy

Data were collected from seventeen schizophrenic patients and seventeen comparable
controls using in vivo proton magnetic resonance spectroscopy. Participant’s
demographic information, details of the medication, imaging sequence, spectroscopy
sequence, spectrum fitting, preprocessing and quantification are described in our previous
studies9,10 and in Chapter 2 of this thesis. Briefly; patients were scanned three times: at
their first assessment in a never-treated state (NT), at 10 months, and at 80 months after
their initial examination. Healthy volunteers were scanned twice (Con1, Con2); the mean
interval between the two assessments was approximately 43 months. In order to observe
the influence of the gray matter segments in the spectroscopy voxel, a correction factor
composed of the tissue percentage was excluded in the quantification procedure. Voxel
segmentation is described in the following section. Metabolite levels in this study were
uncorrected values. Only neuron relevant metabolite levels, N-acetylaspartate (NAA) and
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total glutamatergic metabolites (tGL) are included in the statistical analysis. The SNR of
water and the metabolites are calculated in the time domain. For the SNR calculation, the
signal was taken as the water or metabolite signal at time = 0 (which is proportional to
peak area in the frequency domain). The noise level was defined as the standard deviation
of the last 32 complex pairs in the time domain.

3.2.2

Voxel segmentation

Segmentation analyses for the spectroscopy voxel were performed with ANALYZE and
an in-house software Xstatpack, developed by J Davis. The T1 weighted transverse
images were reoriented based on the anterior-posterior cingulate plane and reformatted to
the isotropic resolution (0.78 × 0.78 × 0.78 mm3) using ANALYZE software. After the
localized spectroscopy voxel was positioned, a quantitative histogram of the signal
intensity was created in each slice with Xstatpack. Thresholds of tissue types were
determined with the histogram. Voxel bins that were registered into gray matter, white
matter or CSF were summed throughout all slices within the spectroscopy voxel
(15 × 10 × 10 mm3). The gray matter fraction was calculated as the volume of gray matter
divided by the total volume of the spectroscopy voxel, 1500 mm3.

3.2.3

Statistics

To probe the interplay between gray matter percentage in the spectroscopy voxel and the
quantified metabolite levels, analyses of variance were performed with a varying
continuous independent variable (i.e. gray matter) in each 3-level repeated measures (NT
vs. 10 months vs. 80 months) and 2 × 2 split plot factorial designs (NT & 80 months vs.
Con1 & Con2). Predictive Analysis of Software (PASW) only handles a constant
covariate throughout the measurement periods per subject with analysis of covariance
(ANCOVA) or Multiple ANCOVA. According to procedures described by Dr. Robert C.
Gardner,11 in ANOVA a varying continuous variable is taken into account using multiple
regression analysis. Metabolite levels, SNRs, peak areas and gray matter are all

66

dependent variables in this study. To perform this multiple regression analysis, gray
matter was selected as a varying independent variable (i.e. covariate). Either metabolite
level, SNR or peak area was set as a dependent variable. The covariate, gray matter, was
“centered” (individual value minus the grand mean of gray matter) in each data analysis.
Centering the gray matter allows the comparison of the intercept, which represents an
expected dependent variable if gray matter was consistent in a comparison (e.g. NT vs.
80 months). The use of a covariate allows all subjects to be normalized with respect to a
confounding variable. Thus, it is statistically possible to control for gray matter values.
The statistical comparison using the adjusted gray matter values was performed in the left
thalamus for: NAA level, tGL level, NAA SNR, tGL SNR, NAA peak area and tGL peak
area. Thresholds for the statistical analyses, 3-level repeated measures and 2 × 2 SPF
analysis, were described in our previous study (Chapter 2).10

3.3 Results
Significant findings in the regression analyses described above and the significance from
our previous study10 are summarized in Table 3-1. The NAA peak area was found to be
significant with the three-level repeated measures in the original 80 months data
(F = 5.55, d.f. = 2,22, P = 0.011). However, there was no significance in the NAA peak
area following the gray matter adjustment (F = 3.65, d.f. = 2,20, P = 0.045 > 0.0167). No
significance in the three-level repeated measures was found in any other variables in
either the original data sets or those with the gray matter adjustment.
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Table 3-1: Statistical significance in the thalamic (a) NAA and (b) tGL levels before
and after the gray matter adjustment.
(a)
Metabolite levels
NAA

SNR

Peak area

Original

ANCOVA

Original

ANCOVA

Original

ANCOVA

Time

0.071

0.185

0.039

0.125

0.011*

0.045

NT vs. 10mo

0.776

0.761

0.835

0.746

0.058

0.165

NT vs. 80mo

0.153

0.262

0.277

0.494

0.980

0.439

10movs. 80mo

0.013*

0.031

0.028

0.065

0.011*

0.027

Group

0.878

0.861

0.323

0.294

0.897

0.429

Time

0.075

0.129

0.128

0.242

0.371

0.823

Group × Time

0.745

0.546

0.668

0.722

0.352

0.174

3-level RM

2x2 SPF

NT vs. Con1

0.692

0.322

0.442

80mo vs. Con2

0.971

0.473

0.826

(b)
Metabolite levels
tGL

SNR

Peak area

Original

ANCOVA

Original

ANCOVA

Original

ANCOVA

Time

0.442

0.585

0.074

0.190

0.104

0.136

NT vs. 10mo

0.638

0.864

0.835

0.756

0.188

0.230

NT vs. 80mo

0.044*

0.970

0.190

0.569

0.733

0.793

10movs. 80mo

0.267

0.317

0.075

0.136

0.066

0.098

Group

0.677

0.656

0.300

0.498

0.875

0.844

Time

0.206

0.865

0.127

0.383

0.148

0.376

Group × Time

0.132

0.970

0.483

0.939

0.069

0.195

NT vs. Con1

0.273

0.233

0.228

80mo vs. Con2

0.724

0.604

0.370

3-level RM

2x2 SPF

Original, original 80 months study; ANCOVA, analysis of covariance (gray matter as a
covariate). *P < 0.0167 (Time, 3-level), *P < 0.025 (NT vs. 10mo, 10mo vs. 80mo),
*P < 0.050 (NT vs. 80mo, comparisons in 2x2 SPF).
Schizophrenia: 10mo, 10months assessment; 80mo, 80 months assessment. NT, nevertreated. Control: Con1, initial scan in healthy volunteers; Con2, follow-up scan in the
healthy volunteers. 3-level RM, three-level repeated measures; 2 × 2 SPF, two-by-two
split plot factorial design (NT & 80 mo vs. Con1 & Con2).
NAA, N-acetylaspartate; SNR, signal-to-noise ratio; tGL, total glutamatergic metabolite
levels (glutamate + glutamine)
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There was a trend toward decreasing thalamic NAA metabolite levels following the gray
matter adjustment between the 10 months and 80 months assessments (F = 6.28,
d.f. = 1,10, P = 0.031) while a significant decrease was found in this comparison in the
original study using a two-tailed paired t-test (t = 2.97, d.f. = 1,11, P = 0.013). Regression
plots at 10 months and 80 months assessment are presented in Figure 3-1. No significant
change was found in gray matter adjusted thalamic tGL levels from NT to 80 months
(F < 0.01, d.f. = 1,14, P = 0.970) while those tGL levels were significantly decreased in the
original 80 months study (t = 2.20, d.f. = 1,15, P = 0.044). Figure 3-2 shows their
correlation plots at NT and 80 months.
No significant change in NAA SNR from 10 months to 80 months was found using the
ANCOVA analysis (F = 4.28, d.f. = 1,10, P = 0.065) while there was a decreased trend in
the original 80 months study (t = 2.54, d.f. = 1,11, P = 0.028). There were no significant
changes in tGL SNR from the NT to the 80 months assessment in either the original data
or those with the gray matter adjustment (Table 3-1).
The NAA peak area at 80 months was significantly decreased compared to 10 months in
the original data sets (t = 3.07, d.f. = 1,11, P = 0.011) while there was a trend toward a
decreasing NAA peak area after the adjustment using the ANCOVA (F = 6.67, d.f. = 1,10,
P = 0.027 > 0.025). No significant changes were observed in the tGL peak area in any
comparisons in either the original or the data with the gray matter adjustment.
There was no significant effect in the 2 × 2 SPF analyses in either the original or the gray
matter adjusted variables (Table 3-1).
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Figure 3-1: Thalamic NAA level adjusted by gray matter in the voxel.
Average NAA level indicates the mean value in the individual measurement period.
Intercept in a regression equation indicates the NAA level if gray matter does not
change between (a) 10 months and (b) 80 months. NAA, N-acetylaspartate
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Figure 3-2: Thalamic tGL level adjusted by gray matter in the voxel.
Average tGL level indicates the mean value in the individual measurement period.
Intercept in a regression equation indicates the tGL level if gray matter does not
change between (a) NT and (b) 80 months. NT, never-treated schizophrenia patient;
tGL, total glutamatergic metabolites (glutamate + glutamine)
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3.4 Discussion
3.4.1

Gray matter effect against NAA and tGL

While the thalamic NAA level in schizophrenia patients was significantly decreased from
the 10 months to the 80 months assessment in the original study (P = 0.013), only a trend
toward a decreasing level was observed in the gray matter adjusted NAA level
(P = 0.031 > 0.025). This result suggests that gray matter in the spectroscopy voxel affects
the NAA level but that the influence is minimal because there was only a trend to lower
levels in this comparison.
NAA SNR and peak area at 80 months were both lower than those at the 10 months
assessment, but the significance of those differences became less prominent following the
gray matter adjustment. The significance of the NAA SNR between 10 and 80 months
moved from a trend (P = 0.028) to non-significant (P = 0.065), while the significance
difference in the NAA peak area between 10 and 80 months (P = 0.011) was reduced to
the level of a trend following the gray matter adjustment (P = 0.027). These results imply
that gray matter in the spectroscopy voxel might be associated with NAA SNR and peak
area as well as NAA metabolite level. However, the statistical p-value in ANCOVA
hovers around the threshold, suggesting the effect of gray matter is subtle because the
SNR and peak area depend more upon the hardware performance rather than tissue
composition in the voxel of interest.
Thalamic tGL level adjusted by gray matter did not significantly decrease from NT to 80
months (P = 0.970) while in the original study, it was found to be significantly decreased
(P = 0.044). Unlike NAA level in the thalamus, the statistical significance in the adjusted
tGL level completely disappeared, suggesting that gray matter loss may be responsible
for the decreased tGL level from NT to 80 months.
No significant change in tGL SNR or peak area was found in either the original study or
the analysis with the gray matter adjustment. The statistical p-value in tGL SNR (NT vs.
80 months) with the gray matter adjustment (P = 0.569) varied from the tGL level without
adjustment (P = 0.190), whereas the p-values in the adjusted and non-adjusted tGL peak
area were quite similar. Consistent statistical significance suggests the tGL peak area was
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not affected by gray matter. It indicates that noise from the data without water
suppression was possibly increased due to the gray matter loss in the spectroscopy voxel
from NT to the 80 months assessment. In fact, different statistical p-values in the tGL
SNR with and without adjustment suggest that metabolite SNR was affected by gray
matter loss. This reduction in gray matter might lead to increased magnetic susceptibility
artifacts, suggesting a structural change.

3.4.2

Physiological or structural change?

Although both NAA and tGL are neuron relevant metabolites, gray matter changes may
affect each of these metabolites differently. While NAA levels tended to be reduced after
the gray matter adjustment (P = 0.031, 10 months vs. 80 months), no significance in the
adjusted tGL level was found (P = 0.970, NT vs. 80 months). NAA level measured with
MR spectroscopy is considered to be a marker of neuronal integrity.12 Significantly lower
NAA levels in schizophrenia patients are often found in the studies of MR spectroscopy
but this does not necessarily imply that there is a loss of neurons.13 In fact, NAA can be
affected by medications without apparent loss of neurons.14 Thus NAA is likely a marker
of neuronal integrity which may be somewhat independent of structural changes
providing some explanation for the minimal effects of gray matter loss on NAA changes
over time in this study.
While NAA level is considered to be associated with neuronal integrity, tGL levels
composed of glutamate and glutamine may be a reflection of synaptic integrity.
Glutamate is stored in the vesicle in the axon terminal and is physiologically activated as
a neurotransmitter in the synaptic cleft, the gap between two neurons.15 Glutamine is
synthesized after glutamate is taken up from the synapse into glial cells. It then diffuses
back to the neuron to be used again as a neurotransmitter. Decreased levels of glutamate
and glutamine measured by MR spectroscopy over time can be related to a physiological
down-regulation of glutamate signaling or a loss of gray matter due to excitotoxicity, loss
of neurotrophic factors or a number of other factors.7 In postmortem studies, Selemon et
al.16 found significantly increased neuronal density in the prefrontal cortex in
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schizophrenia compared to controls which was interpreted as a loss of neuropil or
synaptic connections. Our observation of tGL differences over 80 months10 could be
explained either by a physiological down-regulation or a loss of synaptic gray matter in
the regions studied. Glutamatergic metabolite levels were normalized to some extent by a
correction factor in this study. However, the findings in the present study suggest that
tGL level differences over time in schizophrenic patients disappear when the effects of
gray matter are more carefully controlled. Thus the present results suggest that
differences over time in tGL level in schizophrenic patients are more likely to be related
to loss of neuropil and gray matter than a physiological down-regulation of
neurotransmitter activity.
The significance in the metabolite SNRs and peak areas with the gray matter adjustment
was similar to the analyses without the adjustment. Although statistical p-values in tGL
SNR were changed, both differences in tGL SNR with and without adjustment were nonsignificant. This observation suggests that gray matter loss did not affect the magnetic
susceptibility making it more difficult to detect metabolite changes. However, the
metabolite SNR defined in this study depended on the hardware performance on the date
of the scan.

3.4.3

Implications for excitotoxicity

It is still unclear whether both tGL level and gray matter were decreased at a similar rate
or whether the reduction in tGL level was led by gray matter loss. ANOVA with a
varying continuous variable takes gray matter into account when the statistical
comparisons in the metabolites are conducted. This method only indicates whether gray
matter amount is associated with the metabolite level but does not indicate how
metabolite level might have changed without gray matter loss in our previous 80 months
study.10 It is possible that there might have been an early physiological increase in
glutamatergic metabolites leading to excitotoxicity and loss of synapses and gray matter
which then led to the loss of glutamatergic metabolites. Consequently an early
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physiological increase in glutamatergic activity followed by structural changes in
neuropil cannot be ruled out.

3.4.4

Limitations

Decreased gray matter fraction is possibly caused by a misplacement of the spectroscopy
voxel due to an involuntary movement of the subject before and after the voxel
localization. Subjects were monitored from the superior part of their head during the
experiment. However, it is difficult to detect a head movement along the Z axis,
paralleled to the B0 direction and the head rotation in the anterior-posterior direction. For
instance, if the subject slightly moved to the superior direction before the spectroscopy
acquisition, the localized voxel would be inferior to what was selected using the T1
weight images. Therefore, this spectrum would be composed of the MR signals from the
voxel of interest and from signal outside of the voxel.
Voxel localization might not be identical between the first and follow-up scans. Although
the spectroscopy voxel was localized using landmarks in the brain, the localized voxel
may not be exactly the same as that in the other follow-up scans. Furthermore, the data
was collected by three operators, which might result in a misplacement of the
spectroscopy voxel.
The scan interval in the healthy volunteers was not comparable to that in the
schizophrenia patients. Gray matter loss in controls might be missed due to the shorter
follow-up period. Small gray matter changes make it difficult to detect the correlation to
with the metabolite levels, SNRs and peak areas.
Gray matter in this study may include white matter. Although the thalamus is mostly
composed of the gray matter, it also contains some white matter. Since gray matter is
abundant compared to the white matter, most image pixels are recognized as gray matter
in terms of the contrast. Metabolite levels are different between gray matter and white
matter, even though gray matter and white matter are indistinguishable in this image
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analysis. It may be that the influence of white matter is negligible due to the small
amount of white matter compared to the amount of gray matter.
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Chapter 4

4

The perils of long-term proton magnetic resonance
spectroscopy studies

4.1 Introduction
Neuroimaging techniques are useful in the cross-sectional investigation of abnormalities
in psychiatric disorders.1 However, long-term observation is essential for the
understanding of neurodegenerative disorders such as Alzheimer’s disease and
schizophrenia.2 Magnetic resonance imaging and spectroscopy allow the examination of
long term structural and neurochemical changes. In a previous study, we examined first
episode schizophrenia patients before treatment, followed by 10 months and 30 months
after the medication, using magnetic resonance spectroscopy at 4 Tesla.3
For a long term study however, the reliability of the data is strongly dependent upon the
stability of the hardware during the course of the project. Ideally the Signal to Noise
Ratio (SNR) should be maintained at the same level throughout the project. Despite that,
because MRI systems are complex clinical systems, there will inevitably be hardware
upgrades and/or replacements required to maintain the system. The longer the project
duration, the more likely such difficulties will arise. Our group recently conducted an 80
month follow-up study using magnetic resonance spectroscopy at 4 Tesla. Data was
collected from schizophrenia patients over 7 years and anomalies were found in NAA
and glutamatergic metabolites in schizophrenia patients.4 During the 7 year duration of
this project, there were several upgrades in the MR system. Consequently, a critical part
of internal quality control is to ensure that these measured metabolite concentration levels
are not artificially modified by the changes in the hardware.
SNR is a good measure to track the hardware stability in a long term project.5 In this
present study, SNR was measured in the time domain rather than in the frequency
domain. The advantage of measuring SNR in the time domain is that signal amplitude is
independent of the linewidth while peak intensity in the frequency domain is significantly
dependent on the linewidth. Under the same metabolite concentration level, peak area
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underneath the metabolite spectrum is constant while peak intensity varies with respect to
the linewidth, determined by T2*. If SNR is measured in the frequency domain, peak
intensity should be corrected by linewidth before comparing the SNR. Linewidth is
another good standard to gauge the quality of the spectrum; however it is more affected
by differences in the head structure of the participants and voxel positioning in the brain,
and location with respect to isocentre, rather than hardware changes.
The purposes of this study were: (i) to determine if the SNRs of the MR signals for water,
NAA and tGL in both the schizophrenia and the control groups were significantly
correlated with magnet age; (ii) if there are any significant differences in these SNR
levels throughout the duration of the study, to determine if any hardware modifications
may be responsible, and if so to simulate comparable SNR levels throughout the 10 year
period; and (iii) to evaluate the NAA and tGL concentration levels after replacing the
original data with this simulated data, using the same statistical comparison conducted in
the 80 month study.4 We hypothesize that the significant differences or changes observed
in the metabolite levels in an 80 month study would persist when the original data were
replaced with the SNR adjusted (addition of random noise) data.

4.2 Methods
4.2.1

Participants, imaging and spectroscopy

Data were acquired from 17 schizophrenia patients and 17 healthy volunteers, those who
participated in our previous study.4 Demographic information was exactly the same as
our previous study (see Chapter 2). Schizophrenia patients were scanned before treatment
(NT, never-treated) as well as at 10 months and 80 months after their initial assessment.
Controls were scanned twice (Con1, Con2), and the time period between the two
assessments was approximately 43 months. All experiments were performed with a 4
Tesla whole body scanner located at the Functional and Metabolic Mapping Centre at the
Robarts Research Institute, London, Ontario Canada. All procedures including shimming,
imaging sequence, voxel localization, spectroscopy sequence (STEAM, echo
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time = 20 ms, mixing time = 30 ms, repetition time = 2 s, dwell time = 500 µs), preprocessing, spectral fitting and quantification have been described previously.3,4

4.2.2

SNR, linewidth and magnet age

Signal-to-noise ratio and raw signal were defined in the time domain. Raw signal was
defined as the amplitude of the water or metabolite Free Induction Decay (FID), from
which the recorded signal was decomposed through the fitting procedure introduced in
this section. Noise was calculated from the standard deviation of the last 32 complex
points in the time domain in each suppressed and unsuppressed dataset. Water linewidth
was determined by the fitting procedure and specified as the full width at half maximum
of a fitted single peak Lorentzian component. To examine the MR system stability,
correlation analyses were performed versus magnet age for water linewidth, and SNR of
water, NAA and tGL. The magnet age was defined with respect to the date of the earliest
scan (August 27, 1997) in this study. For this discussion we are using ‘magnet age’ to
define the age of the entire MR system as the magnet was not changed over the 7 years,
whilst most of the other components were replaced and/or modified during the study (e.g.
gradients, gradient amplifiers, receiver electronics, RF amplifier, MR console);
Magnet age [year] = {(Date of scan) – (August 27, 1997)} / 365 days.
This correlation analysis was performed at each measurement period in each group (e.g.
NT, Con 1) as well as a correlation combining all the samples in the schizophrenia group
(NT, 10 months plus 80 months) and similarly for the control group (Con1 plus Con2).
The latter correlations are not meaningful statistical analyses because each sample is not
truly independent in terms of subject. Nevertheless, we performed this correlation
analysis only to detect a significant change in SNR at a particular time period over the
entire magnet age.
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4.2.3

Random noise

Presumably because of a hardware variation or other factors related to the ‘sample’, the
SNR may vary from one time to another. The source of this hardware difference will be
addressed in the discussion; however the goal here is to demonstrate that the differences
in SNR were not responsible for observed changes in metabolite levels. In an attempt to
make the SNR consistent throughout the study, the time point where SNR is determined
to be best, we added extra noise into the raw data in the time domain using software
coded using Matlab7 (Matlab, The Mathworks, Natick, MA). Noise was only added to
the data collected at a particular time period, at which time the SNR of water and the
metabolites were significantly higher than those collected at other time points within the
study period. The time period with a reduced noise, and hence elevated SNR, was
identified by the correlation analysis between SNR and magnet age. Discrete pseudorandom noise (3008 data points) was produced in the time domain. The noise amplitude
was estimated from the mean noise level - the standard deviation of the last 32 complex
points. The random noise amplitudes were added to each real and imaginary point
utilizing the phase information obtained from the water reference of each dataset. Preprocessing, spectral fitting and quantification described in our previous study3,4 were
repeated for the simulated spectra (with extra noise). In order to reduce a bias, all
procedures described in this section were repeated in triplicate. Quantified metabolite
levels were averaged across the three trials.

4.2.4

Statistical analyses

Statistical analyses were completed using statistical software PASW Statistics version
18.0.0 for Windows. Correlation analyses were performed versus magnet age for the
SNR, linewidth and noise level after the addition of extra noise with the Pearson product
moment coefficient (P = 0.001). As indicated above, this was performed at each
measurement period in each group, including all of the samples in the patient group, and
including all of the samples in the control group.
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Quantified NAA and tGL levels were then compared using the same statistical method
described in our previous study.4 Correlation analyses were also conducted with respect
to the subject age instead of magnet age at each measurement period. This is to identify
whether there are changes within the group due to patient age.

4.2.5

SNR simulation: precision in the metabolite quantification

In this study, random noise was added to datasets in the time domain data for the time
point that was identified to have a higher SNR (lower noise) than the remaining data sets
in the study duration. The origin of this difference will be discussed later. In order to
understand how the noise level of the data affects the fitting of the metabolites, one
characteristic spectrum was selected from the entire study set. This dataset was fit to
determine the metabolite levels as described above. The ideal noiseless fit was taken as
an ideal spectrum and 149 different noise sets were added to this spectrum in the time
domain using the same approach described in the “random noise” section of this study.
Pre-processing, spectral fitting and quantification were repeated for the simulated spectra.
These quantified spectra were sorted by NAA SNR, chosen to be between 1.34 and 8.49,
as this is the SNR range observed the original 80 months study (as determined below).
Groups (n = 11) were created based on NAA SNR (group averages: 1.75, 2.19, 2.84. 3.25,
3.71, 4.22. 4.77. 5.34. 5.81, 6.25 and 7.13). Quantified metabolite peak areas were
averaged in each group.

4.3 Results
4.3.1

Correlation with respect to magnet age (across
measurement periods)

In the original data sets, NAA SNR decreased with magnet age in the anterior cingulate
(r = -0.460, P = 0.002, N=44) and the thalamus (r = -0.460, P = 0.001, N=45) in
schizophrenia (i.e. combining NT, 10 months and 80 months). The correlation of NAA
SNR versus magnet age in the thalamus is presented in the top-left of Figure 4-1(a).
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Figure 4-1: NAA signal-to-noise ratio in the left thalamus in schizophrenia versus
magnet age.
Plot at the top-left (a) is a correlation across the measurement periods (n = 45). The
rest of the plots are the correlations at each measurement period; NT (b), 10 months
(c) and 80 months (d).

Thalamic tGL SNR in the schizophrenia group also demonstrated a trend to decrease over
magnet age (r = -0.423, p = 0.004). There was no significant correlation between noise
levels in the water suppressed data and magnet age in the anterior cingulate (r = 0.379,
P = 0.012) and the thalamus (r = 0.372, P = 0.012) in schizophrenia patients. Figure 4-2
represents the change in the metabolite noise in the left thalamus with respect to the
magnet age in schizophrenia. None of the variables in the control group (Con1 plus
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Con2) was significantly correlated with the magnet age in both the anterior cingulate and
the thalamus.

Figure 4-2: Metabolite noise in the left thalamus in schizophrenia versus magnet
age.
Noise is calculated from the last 32 complex points in the time domain. Plot at the
top-left (a) is a correlation across all data samples (n = 45). The rest of the plots are
the correlations at each measurement period; NT (b), 10 months (c) and 80 months
(d).

In these plots, there is an apparent trend toward lower noise levels during the first two
years of the study (Figure 4-2). This might explain some elevated SNR, for example the
water SNR, observed during that time period. This was particularly curious because of
the gradient coils upgrade occurring at that specific time. One possible culprit is a change
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in the digital filter that occurred at that time. Because of these hardware upgrades, a
possible transition time was defined at 2 years in magnet age. The noise manipulation
described in “random noise” in the method section was performed in the data collected
only in the first 2 years since August 27, 1997, the oldest data set in this data analysis.
Because of the timing of the measurements, extra noise was added to the six data sets at
NT and 10 months assessment in the schizophrenia group and four data sets at Con1 in
the control group.

4.3.2

Metabolites SNR vs. magnet age (at the individual
measurement periods)

Correlations with respect to the magnet age at each measurement period are summarized
in Table 4-1. In the left anterior cingulate, tGL SNR was significantly decreased over
magnet age at 10 months assessment in schizophrenia (r = -0.809, P = 0.001), and there
was a trend toward a decrease at NT (r = -0.741, P = 0.002). There was a trend toward
decreasing NAA SNR at NT (r = -0.714, P = 0.003) and 10 months assessment (r = -0.750,
P = 0.005) in schizophrenia. Metabolite noise was significantly increased at 10 months in
schizophrenia (r = -0.828, P = 0.001). None of the other correlations were significant in
either schizophrenia or controls in the anterior cingulate.

85

Table 4-1: Pearson product-moment coefficients with respect to the magnet age
before and after adding extra noise into the first 2 years data.
(a)
Anterior
Cingualte

NT

10 mo

80 mo

All

N=15

N=14

N=16

N=44

Original

Original

ns

ns

With
noise
ns

ns

With
noise
ns

ns

ns

ns

ns

ns

ns

Ns

ns

ns

ns

ns

ns

ns

Ns

ns

0.828**

ns

ns

ns

ns

NAA SNR

-0.714*

ns

-0.750*

ns

ns

-0.460*

ns

tGL SNR

-0.741*

ns

-0.809**

-0.747*

ns

ns

ns

NAA level

Ns

ns

ns

ns

ns

ns

ns

tGL level

Ns

ns

ns

ns

ns

ns

ns

Water linewidth

Ns

With
noise
ns

Water SNR

Ns

Water noise
Metabolite noise

Original

Original

(b)

Thalamus

NT

10 mo

80 mo

All

N=16

N=12

N=17

N=45

Original

Original

ns

ns

With
noise
ns

ns

With
noise
ns

ns

-0.810**

ns

ns

ns

0.426*

Ns

ns

ns

ns

ns

ns

ns

Metabolite noise

0.682*

ns

0.755**

ns

ns

ns

ns

NAA SNR

-0.689*

ns

-0.765*

ns

ns

-0.460**

ns

tGL SNR

Ns

ns

-0.806**

ns

ns

-0.423*

ns

NAA level

Ns

ns

ns

ns

ns

ns

ns

tGL level

Ns

ns

ns

ns

ns

ns

ns

Water linewidth

Ns

With
noise
ns

Water SNR

Ns

Water noise

Original

Original

Significant r-values in schizophrenia in the (a) anterior cingulate and (b) thalamus are
shown in this table (**P < 0.001, *P < 0.005). R-values in the original 80 months study
(before adding noise) are presented in the left column (Original) in each NT, 10mo and
All group section as well as 80 mo column. Statistical values after the noise manipulation
are presented in the right column (With noise) with italic font in each section except 80
mo column. Extra noise were added in the data sets, collected in the first 2 years (six data
sets of each NT and 10 mo).
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In the left thalamus, water SNR at 10 months assessment in schizophrenia was
significantly decreased over magnet age (r = -0.810, P = 0.001). There is a trend toward a
negative correlation with magnet age for NAA SNR at NT (r = -0.699, P = 0.003) and 10
months (r = -0.765, P = 0.004) and tGL SNR at the 10 months assessment (r = -0.806,
P = 0.002). Figure 4-1 (b, c, d) presents the correlations between NAA SNR in the
thalamus and magnet age. There is a trend for metabolite noise to increase over magnet
age at both NT (r = 0.682, P = 0.004) and 10 months (r = 0.755, P = 0.005) (Figure 4-2).
No significant correlation was found in controls in the thalamus.
Correlations after the noise manipulation were presented in the right column in NT and
10 months in Table 4-1. Extra noise was added to the data collected in the first 2 years
and replaced with the original data sets. This noise simulation was not performed in the
data in the 80 months group because these data were collected beyond the transition time
(i.e. first 2 years in the magnet age). An observed trend toward decreasing tGL SNR over
magnet age persisted in the anterior cingulate after adding noise (r = -0.747, P = 0.002).
No other significant correlation was observed after the noise simulation in any other
variables, measurement periods, regions and groups.

4.3.3

Metabolite levels after adding random noise

Mean metabolite levels in the original 80 months study and in these data with extra noise
are presented in Figure 4-3 (anterior cingulate) and 4-4 (thalamus). There was a trend
toward decreasing NAA level from 10 months to 80 months assessment in the left
anterior cingulate in the original data (P = 0.031 > 0.025) but no significance was
observed in the same data after adding the random noise (P = 0.114). There was no other
significant difference between the original and simulated data in the left anterior
cingulate. Thalamic NAA level at 80 months was significantly decreased from 10 months
in the original data (P = 0.013) (Figure 4-4). After adding the noise, this was no longer
significant (P = 0.029 > 0.025) but there was a trend toward a decreasing level. The tGL
level at 80 months was significantly decreased from NT in schizophrenia in the original
data (P = 0.044) and the data with extra noise (P = 0.024).
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Figure 4-3: Metabolite levels in the anterior cingulated before and after data
manipulation.
Anterior cingulate NAA (a) and tGL (b) concentration levels in the 80 months study
(Original data) and the same data with adding random noise (With extra noise).
Error bar indicates the group standard deviation in each measurement period.
Extra noise were added into 6 data sets in each NT (n = 15) and 10mo measurement
(n = 14), as well as 4 data sets in Con1 (n = 17).
Measurement period: NT, never-treated; 10mo, 10 months assessment; 80mo, 80
months assessment; Con1, control at scan #1; Con2, control at scan #2. Metabolites:
NAA, N-acetylaspartate; tGL, sum of glutamate and glutamine.
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Figure 4-4: Metabolite levels in the thalamus before and after the data
manipulation.
Thalamic NAA (a) and tGL (b) concentration levels in the 80 months study
(Original data) and the same data with adding random noise (With extra noise).
Error bar indicates the group standard deviation in each measurement period.
Extra noise were added into 6 data sets in each NT (n = 16) and 10mo measurement
(n = 12), as well as 4 data sets in Con1 (n = 17). **P < 0.025, *P < 0.050.
Measurement period: NT, never-treated; 10mo, 10 months assessment; 80mo, 80
months assessment; Con1, control at scan #1; Con2, control at scan #2. Metabolites:
NAA, N-acetylaspartate; tGL, sum of glutamate and glutamine.

4.3.4

SNR simulation: precision in the metabolite quantification

In this study, noise was added to some time points, and the potential impact on metabolite
levels was investigated. It is therefore important to know whether and to what extent
modifying the noise level will alter the fitting of the metabolites. Figure 4-5 represents
the variation of 7 quantified metabolite levels with respect to NAA SNR. In this study,
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the addition of noise for the first 2 years of an 80 month study caused the NAA SNR in
the time domain to decrease by approximately 25% (from 4.818 to 3.612). The grand
mean was calculated from the data in the first 2 years of the study, including both groups
(schizophrenia & control) and both regions (anterior cingulate & thalamus). These
average SNR before (dashed line) and after adding the noise (solid gray line) are shown
as vertical lines in Figure 4-5. The average NAA SNR drop in the anterior cingulate and
the thalamus was 25.5% and 24.7%, respectively. Figure 4-6 represents the changes in
quantified NAA metabolite level with respect to the simulated NAA SNR. Error bars
represent the group standard deviation of the NAA level in each SNR group. The
Coefficient of Variation (CV) around the mean NAA SNR before and after adding noise
is approximately 10.6% and 11.9%, respectively. The CV for the glutamate level
degrades from 13.3% to 21.1%, and similarly for the glutamine level, from 25.2% to
36.0%. Figure 4-7, 8 and 9 represent the quantified glutamate, glutamine and tGL levels
with respect to the NAA SNR, respectively.

90

Figure 4-5: SNR simulation.
Quantified metabolite levels with respect to the NAA signal-to-noise ratio in the time
domain. 149 spectra were simulated with using a noise-free spectrum. These spectra
are sorted into 11 different NAA SNR. Two vertical lines show the average NAA
SNR before (dashed line) and after (solid gray line) adding the extra noise in the
first 2 years data in 80 months study. The averages are taken among the first 2 years
data, including 6 data sets of each NT and 10 months as well as 4 data sets in Con1
in both anterior cingulate and thalamus.
Cho, choline; Gln, glutamine; Glu, glutamate; Myo, myo-inositole; NAA, Nacetylaspartate; tCr, total creatine; tGL, total glutamatergic metabolite (Glu+Gln).
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Figure 4-6: SNR simulation, NAA level.
Quantified NAA levels with respect to the NAA SNR. Error bar indicates the
standard deviation in each group sorted by NAA SNR. Two vertical lines show the
average NAA SNR before (dashed line) and after (solid gray line) adding the extra
noise in the first 2 years data in 80 months study. The averages are taken among the
first 2 years data, including 6 data sets of each NT and 10 months as well as 4 data
sets in Con1 in both anterior cingulate and thalamus.
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Figure 4-7: SNR simulation, glutamate level.
Quantified glutamate levels with respect to the NAA SNR. Error bar indicates the
standard deviation in each group sorted by NAA SNR. Two vertical lines show the
average NAA SNR before (dashed line) and after (solid gray line) adding the extra
noise in the first 2 years data in 80 months study. The averages are taken among the
first 2 years data, including 6 data sets of each NT and 10 months as well as 4 data
sets in Con1 in both anterior cingulate and thalamus.
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Figure 4-8: SNR simulation, glutamine level.
Quantified glutamine levels with respect to the NAA SNR. Error bar indicates the
standard deviation in each group sorted by NAA SNR. Two vertical lines show the
average NAA SNR before (dashed line) and after (solid gray line) adding the extra
noise in the first 2 years data in 80 months study. The averages are taken among the
first 2 years data, including 6 data sets of each NT and 10 months as well as 4 data
sets in Con1 in both anterior cingulate and thalamus.
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Figure 4-9: SNR simulation, tGL level.
Quantified total glutamatergic metabolites (tGL) with respect to the NAA SNR.
Error bar indicates the standard deviation in each group sorted by NAA SNR. Two
vertical lines show the average NAA SNR before (dashed line) and after (solid gray
line) adding the extra noise in the first 2 years data in 80 months study. The
averages are taken among the first 2 years data, including 6 data sets of each NT
and 10 months as well as 4 data sets in Con1 in both anterior cingulate and
thalamus. tGL: total glutamatergic metabolites (glutamate + glutamine)

4.3.5

NAA SNR vs. subject age

No significant correlation with respect to the subject age was found either in the anterior
cingulate or the thalamus at any measurement periods, including all measurement periods
in both groups. The top plot in Figure 4-10 shows the correlations between NAA SNR
and the subject age in schizophrenia. The bottom plot in Figure 4-10 represents the same
correlation following the addition of the pseudo-random noise. Figure 4-11 presents the
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thalamic NAA SNR with respect to the subject age in controls. The original data is shown
in the top plot while the bottom panel shows the data with the extra noise.

Figure 4-10: Correlations between subject age and thalamic NAA signal-to-noise
ratio in schizophrenia
NAA signal-to-noise ratio at all measurement periods (N = 45) were involved in this
correlation analysis. Top plot (a) indicates the original 80 months study. Bottom plot
(b) indicates the data after the noise simulation, applied to the 12 data sets (6 of each
NT and 10 months) collected in the first 2 years
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Figure 4-11: Correlations between subject age and thalamic NAA signal-to-noise
ratio in controls
NAA signal-to-noise ratio at all measurement periods (N = 33) are involved in this
correlation analysis. Top plot (a) indicates the original 80 months study. Bottom plot
(b) indicates the data after the noise simulation, applied to the 4 data sets in Con 1
group collected in the first 2 years. Con 1, initial scan for the controls; Con 2,
follow-up scan for the same controls.
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4.4 Discussion
4.4.1

Correlations in SNRs with magnet age

Metabolite SNRs in both the anterior cingulate and the thalamus in schizophrenia were
significantly or demonstrated a trend to be decreased over magnet age while there was no
correlation in those SNRs in the control group. These decreases in SNRs may be a result
of or enhanced by the hardware changes. Several hardware components in our MR
system were upgraded or replaced in the first two years. This partially explains why no
significant correlation against magnet age was found in controls, who were scanned much
later than schizophrenia patients. In addition, only four control scans were performed in
the first two years while twelve scans (six scans in each NT and 10 months) were
completed in the schizophrenia group.
Despite the significant drop in metabolite SNRs, no SNR change was confirmed in the
routine QA, which was performed by a system manager every week. Quality control in
our 4T MR system was conducted by taking a magnitude image with the echo planar
imaging (EPI) sequence using an identical phantom each week. It is possible that SNRs
measured by a spectroscopy sequence are more sensitive compared to SNRs determined
using an imaging sequence. Indeed, water SNR in this study was not significantly
correlated with the entire magnet age in any regions or groups.
Another possible explanation is the digital filter. In our protocol, the digital filter was
manually turned on during the MRS acquisition to reduce the noise in the first two years
of the study. At this point in time, the hardware upgrade removed the need for the digital
filter, and the operating protocol was adjusted as such. Therefore, metabolite SNRs in the
first two years might be higher than SNRs in the remaining years. Water SNRs were not
as high as metabolite SNRs in the first two years. This suggests noise reduction by the
digital filter might be insufficient to improve the water SNR because water signal was too
high to be affected by the noise reduction. Since metabolite SNRs were influenced by the
hardware replacement and/or the digital filter, we were concerned whether the observed
differences in metabolite levels in our 80 months study4 could be attributed to this
artifact. It will be discussed in the next section whether the differences in metabolite
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levels observed in the 80 months study are affected by the changes in SNRs caused by the
addition of the random noise.

4.4.2

Metabolite concentration levels: influence of random noise

Thalamic tGL level was still significantly decreased at 80 months from NT in
schizophrenia patients even though some of the data sets in NT were replaced with the
manipulated data. The differences were more significant (P = 0.024) compared to the
original data sets (P = 0.044). Thalamic NAA level in schizophrenia, however, only
showed a trend toward decreasing from 10 months to 80 months after the data
manipulation (P = 0.029) while significant decrease was observed before adding extra
noise (P = 0.013). The significance in the anterior cingulate NAA level (P = 0.031)
worsened after extra noise was added (P = 0.114). This data is artificial in the sense that
noise has been added in the first two years of data to make the SNR comparable across
the study duration. However this still demonstrates that a hardware modification such as
this may be responsible for a trend or a significant finding in the data that is not
physiological in nature. Thus particularly in a long-term study, significantly different
SNRs may skew statistical comparisons.
The influence of the noise is inconsistent between NAA and tGL levels. This most likely
originates because the NAA level is due to a single metabolite while tGL level is
composed of two different metabolites. tGL level was found to be higher than the NAA
level, and the standard deviation of the tGL level is lower than that of NAA. Therefore,
tGL is more stable than NAA in terms of the quantified metabolite level in the
spectroscopic study. A possible explanation for the differential improvement in the
significance in the thalamus and anterior cingulate would be the metabolite SNR in the
original in-vivo data. Overall, SNR measured in the anterior cingulate spectra is lower
than those in the thalamus spectra. Lower SNR in the anterior cingulate is caused by the
decreased sensitivity due to the sinus cavity. Lower SNR spectrum often leads to misfit
and inconsistent spectral fitting compared to the higher SNR spectra. Therefore, spectra
in the anterior cingulate are vulnerable to increasing noise level compared with the

99

spectra in the thalamus. The effect of the SNR changes on metabolite quantification will
be discussed with an SNR simulation in the next section.

4.4.3

SNR simulation: SNR and precision of the metabolite
quantification

Metabolite quantification is sensitive to the SNR. In this SNR simulation, all quantified
metabolite levels vary within the actual range of the NAA SNR in the 80 months study
(Figure 4-5). The standard deviation of quantified metabolite levels are observed to
worsen as the SNR of NAA decreases. In particular, glutamate and glutamine levels show
a large standard deviation at NAA SNR less than 3 (Figure 4-7 and 4-8). Insufficient
SNR leads to inconsistent quantification because fitting of the lower SNR spectra is
dependent on the noise signal at the data collection.
At the higher NAA SNR, group standard deviations are more consistent compared to
those at lower SNR but metabolite levels still vary. This simulation suggests that it is
very important to maintain the SNR at a constant level, especially in longitudinal studies.
Significant SNR changes between or within subjects may lead to errors in statistical
comparisons.
One key finding of these simulations is that noise level may impact the fitting of the
metabolite spectra. In fact, Figure 4-5 suggests that changing the SNR to below 3 would
result in a very different fit of the metabolites. However over the change in SNR in this
study, Figures 4-5 to 4-9 suggest that a significant change in the metabolite level is not
expected. Thus the change in noise level of this simulation is not expected to impact the
fit of the metabolite level.

4.4.4

Limitations

Either metabolite levels or SNRs were not corrected for subject age. Neuronal
metabolites such as NAA are expected to decrease as the subjects age.6 High metabolite
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SNR at the first two years might be influenced by subject age as the data were collected
at an earlier age compared to their 80 months assessment. However, since there is no
correlation between metabolite SNR and subject age (Figure 4-10 and 4-11), an age effect
for the metabolite SNR is less likely in this study.
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Chapter 5

5

Thesis summary

5.1 Results summary and implications
This thesis presents the results of a long-term study of schizophrenia, which is an
extension of a previous longitudinal study.1 In the initial study, it was reported that the
initially elevated glutamine level in schizophrenia patients decreased over the 30 month
assessment period. Chapter 2 of this thesis presents a longitudinal study to investigate
whether or not these findings persist out to 80 months in the same population. The
driving hypothesis of this study was as follows:

Hypothesis 1: Significantly higher glutamatergic metabolites during the first episode will
decrease in schizophrenia over the 80 months. Glutamatergic metabolite decreases will
correlate with widespread gray matter losses and social functioning at a 7 year followup.
In Chapter 2, we found that glutamatergic metabolites and NAA levels as well as gray
matter volume were significantly decreased in schizophrenia over 80 months. Reductions
in those metabolite levels were significantly correlated with gray matter loss in the
regions associated with schizophrenic symptoms. These results suggest that physiological
and structural deterioration persist in schizophrenia for at least 7 years. Significant
correlations suggest that an excitotoxic process may lead to a neuronal dysfunction,
which is eventually observable as widespread gray matter loss.
Loss of glutamatergic metabolite levels were inversely correlated with the Life Skills
Profile (LSP) rating scale, a standardized social functioning, in schizophrenia at 80
months assessment. Glutamatergic reduction over 80 months was larger in a patient with
lower LSP score, which indicates impaired social functioning. This negative correlation
suggests that glutamatergic metabolite levels may reflect deteriorating social functioning
in schizophrenia.
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These results confirm our first hypothesis that glutamatergic metabolites and gray matter
decreased over time. The loss of metabolite was significantly correlated with the gray
matter losses, and social functioning was negatively correlated with the loss of
glutamatergic metabolite levels. This long-term study demonstrates evidence of
neurodegenerative processes in schizophrenia correlating metabolite levels with the
physiological and structural changes, as well as social functioning. This is the first study
to demonstrate these findings.
However coincident reductions in neuronal metabolite levels and gray matter volume
raise a further question. Is it possible that structural changes in the brain resulting in
change in gray matter volume are affecting metabolite levels such as glutamatergic
metabolites and NAA? The purpose of Chapter 3 of this thesis was therefore to probe
whether or not changes in the gray matter in the spectroscopy voxel could be responsible
for observed changes in metabolite levels. To answer this question, the following
hypothesis was derived:

Hypothesis 2: Loss of glutamatergic metabolites in first episode patients over time will be
related to gray matter loss in the voxel of interest but will not be significantly affected by
signal-to-noise changes associated with gray matter loss. NAA levels will be less likely to
be affected by gray matter loss in the voxel of interest or signal-to-noise changes.
In Chapter 3, we examined whether decreased metabolite levels were significantly
associated with the loss of gray matter in the long-term study (Chapter 2). Comparing the
metabolite levels adjusted by the gray matter in the voxel of interest, significance in NAA
levels hovered around the threshold while significance in the glutamatergic metabolite
levels turned out to be non-significant. This suggests that gray matter in the spectroscopy
voxel may not be responsible for the NAA levels but possibly for the glutamatergic
metabolite levels. This therefore suggests that significantly decreased glutamatergic
metabolite levels in the long-term study may be explained through the loss of neuropil,
which is observed as gray matter loss. The subtle association between gray matter and
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NAA level may be partially explained by the connection between 1H MRS measured
NAA levels and neuronal integrity.
Significances in metabolite signal-to-noise ratio were unchanged by the gray matter
adjustment. Despite the significant loss of gray matter in the voxel of interest, the
influence of the gray matter on the metabolite signal-to-noise ratios was likely minimal. It
suggests that signal-to-noise ratio defined in this study is more affected by the hardware
performance and the data acquisition than the anatomical structure and location in the
head.
These results confirm the hypothesis that gray matter may be associated with the
glutamatergic metabolite levels but not with the NAA levels. This line of inquiry led to a
significant amount of discussion surrounding hardware performance, and factors that may
impact the signal-to-noise ratio. It is important for example that the metabolite levels and
gray matter volumes were measured under the same experimental condition in the MR
system. That way observed differences were due to biological changes and not a result of
the hardware. This is an even more important consideration when undertaking a long
term study such as ours that spanned 7 years.
It was noted from our long term study that due to a hardware modification, there was a
change in the noise level of the system. Hardware replacements and/or upgrades are
inevitable, particularly as the duration of a study becomes longer. Although our MR
technician carefully maintained the MR system, with rigorous quality control, this change
in the system noise may have affected the metabolite signal-to-noise ratio in our study. It
then became crucial to understand whether or not the signal-to-noise ratio changed due to
this hardware modification, and if so, whether or not the metabolite quantification was
affected. In Chapter 4, a series of data manipulations and simulations were presented to
answer these questions. It was hypothesized that:

Hypothesis 3: Significant differences in brain metabolites observed in our long-term
study would persist after data manipulation to simulate a constant signal-to-noise ratio
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throughout this study. Thus, Signal-to-noise ratio changes during our long-term study
were not a major issue if the changes are modest.

Chapter 4 demonstrated the influence of signal-to-noise ratio on the metabolite
quantification. Data manipulation, adding extra noise into the corresponding data, in the
long-term study (Chapter 2) showed that the impact of signal-to-noise ratio is different
for each of the individual metabolites. Significance in the NAA levels reported in the
long-term study turned out to be a trend while the significance in tGL levels was
improved after the data manipulation. This implies a risk in long term studies that an
errant or inconsistent signal-to-noise ratio may skew the statistical significance of the
quantified metabolite levels.
A signal-to-noise simulation was conducted to examine how metabolite signal-to-noise
ratios affect the quantified metabolite levels. Differing amounts of noise were added into
a noise-free spectrum generated from a data set in the long-term study. Lower signal-tonoise leads to an increased standard deviation in each metabolite level in groups of
measurements having similar signal-to-noise ratios in this study. Quantification precision
is decreased in those spectra with lower signal-to-noise. This simulation showed a
potential risk that larger distributions of signal-to-noise ratio within a subject group may
lead to difficulties in observing statistically significant differences or changes.
Thus these results confirm hypothesis 3, that these simulations in Chapter 4 demonstrate
that significance in metabolite levels in the long-term study (Chapter 2) persisted with the
addition of extra noise. Metabolite signal-to-noise ratios in the long-term study were
maintained within a reasonable range, holding a similar precision in the metabolite
quantification throughout the study. A broad range of signal-to-noise ratios however may
lead to inconsistent metabolite quantification and a distorted statistical significance. This
is crucial when differences or changes are reported using the statistical significance. To
our knowledge, this is the first study to examine the role of hardware and signal-to-noise
over long periods of time in this type of clinical study.
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In summary, this thesis demonstrated the following using in vivo 1H MRS: (1) evidence
that glutamatergic and NAA metabolite levels decline in schizophrenia for at least 7
years, (2) decreases in glutamatergic metabolite levels are associated with widespread
gray matter losses and decreases in social functioning in schizophrenic patients, (3)
decreases in glutamatergic metabolites may be accounted for at least in part by a loss of
neuropil within the voxel of interest although an earlier degenerative process resulting in
both the loss of neuropil and decreased glutamatergic metabolites cannot be ruled out,
and (4) although hardware changes over time can influence signal-to-noise, differences in
metabolite level persisted demonstrating that it is possible to carry out a long-term MRS
study in a clinical population.
These findings have a number of implications for the understanding of the
pathophysiology of schizophrenia as well as the feasibility of long-term MRS studies of
clinical disorders. On the whole, findings would be consistent with degeneration related
to glutamatergic excitotoxicity.2 However, they do not rule out an early
neurodevelopmental lesion related to genetic or environmental factors which might have
been uncovered by cortical pruning which occurs during adolescence. The findings could
also be accounted for in part by a genetically programmed loss of neuropil caused by a
loss of nerve growth or other factors but the finding of increased glutamatergic
metabolites without a change in gray matter in the first assessment would not be
consistent with this explanation. If a loss of nerve growth factors caused the loss of gray
matter, loss of gray matter would be expected at the first assessment. The effect of
medication cannot be ruled out as well but it appears unlikely as there were few
differences in gray matter and no differences in glutamatergic metabolites between the
initial assessment before medication and the follow-up 10 months later on medication. It
is possible that chronic medication effects may have influenced metabolite levels and
gray matter but there appeared to be few significant correlations between the dose of
medication and gray matter loss and no significant correlation between the dose of
medication and metabolite levels.
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Findings in the present studies are consistent with a parallel series of 31P MRS studies
which demonstrated increased membrane breakdown products in first episode
schizophrenic patients in regions associated with increased glutamatergic metabolites.3 A
follow-up of these patients showed diminished membrane breakdown products over time
in these regions in keeping with the loss of glutamatergic metabolites.4 An increase in
membrane breakdown products was also demonstrated in a subsequent study5 in regions
showing later loss of gray matter suggesting that a degenerative process may precede the
loss of gray matter. The findings of this thesis combined with the 31P MRS studies
implicates glutamate as a possible target of therapeutic intervention in this disorder.
Current treatments do not prevent social deterioration. The association between the loss
of glutamatergic metabolites and social functioning in this study suggests that it might be
possible to arrest this process with pharmaceuticals that target glutamate.
One recommendation arising from this study would be that researchers engaged in long
term spectroscopy studies not only track the daily quality assurance using the SNR of a
uniform phantom, but also that the metabolite signal and noise be monitored on a regular
basis, in particular, before and after major hardware upgrades. In this way the potential
risk of hardware signal/noise changes impacting the metabolite quantification can be
mitigated.

5.2 Future work
This thesis is composed of data acquired at 4 Tesla, which provided a good separation
between glutamate and glutamine spectra. As described in Chapter 2 and 3, glutamine
levels measured with 1H MRS are better indicators for the glutamate neurotransmission,
which might cause an excitotoxicity in schizophrenia. In Chapter 2, these two metabolite
levels were quantified separately. Using a higher magnetic field strength such as 7 Tesla
would be the logical next step to improve the spectral resolution. Improved signal-tonoise ratio is expected at 7 Tesla compared to at 4 Tesla as the signal-to-noise ratio is
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proportional to the magnetic field strength. High signal-to-noise ratios may improve a
measurement of low concentration metabolites in the human brain such as GABA, which
is synthesized from glutamate with an enzyme glutamic acid decarboxylase.
High signal-to-noise ratio also supports better spectral fitting and the precision of the
metabolite quantification. Using a phased array coil also improves the signal-to-noise
ratio when compared to a head coil. 32 channel phased array coils are available. Using a
phased array coil at 7 Tesla, our laboratory conducts functional magnetic resonance
spectroscopy (fMRS), which allows the measurement of dynamic metabolite changes
from a functionally activated area determined by fMRI. It would be interesting for
example whether external stimuli might impact observed metabolite changes, helping to
understand the disease mechanism, or perhaps hinting at other approaches to disease
management. We are also utilizing two dimensional chemical shift imaging, which
measures the metabolite levels within the entire slice. Two dimensional CSI will enable
the evaluation of metabolite changes simultaneously over a wider area. Perhaps
metabolite changes in one region may reflect similar changes in other regions of the brain
not presently under consideration, further enhancing our understanding of the disease
mechanism.
Updating a priori knowledge is necessary to improve the spectral fitting. If a metabolite
or macromolecule component is missing in the a priori information, the fitting algorithm
attempts to compensate the missing peak with the existing components, resulting in a
quantification error. An automated fitting procedure minimizes a user-dependent factors
such as setting the seeding values, which are required to run the Fitman program and are
manually chosen in each spectrum. The Fitman program uses the Levenberg-Marquardt
minimization algorithm that seeks the global minima, the best compromise between raw
data and fitting. If the seeding value is not properly set, the fitting algorithm may find the
local minima and not the best fit global minimum.
Some difficulties associated with longitudinal studies were discussed in Chapter 4. A
longitudinal study is a powerful way to investigate progressive disorders such as
schizophrenia and Alzheimer’s disease. The longer the follow-up period is, however, the
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more likely hardware upgrades or replacements are required. Thus, the signal-to-noise
ratio might be different before and after the hardware changes. We demonstrated that a
wide range of signal-to-noise ratio might distort the metabolite quantification and
statistical comparison in Chapter 4. Measuring the water signal-to-noise ratio in vivo as
well as the regular quality control with a phantom would help to maintain the quality of
the spectra in a longitudinal study.
To maintain a reasonable range for the signal-to-noise ratio, the same head coil could be
utilized with similar MR systems. If the signal-to-noise ratio was significantly elevated
due to a hardware upgrade during a project, a possible solution to maintain a certain
signal-to-noise ratio would be to transfer the head coil to another MR system, in which a
similar signal-to-noise ratio is expected.
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Appendices
Appendix A: No differences in metabolite levels in mood
disorder patients compared to healthy volunteers
Nery et al.1 reported no statistical differences in the metabolite levels between 37
unmedicated participants with major depressive disorder (MDD) and 40 matched healthy
controls. They measured the metabolites N-acetyl aspartate (NAA), glutamate (Glu),
phosphocreatine plus creatine (PCr + Cr), choline-containing compounds (GPC + PC),
myo-inositol (Myo) and Glu plus glutamine (Glu + Gln) in a 2.0 × 2.0 × 2.0 cm voxel in
the left dorsolateral prefrontal cortex using in-vivo proton magnetic resonance
spectroscopy (1H MRS) at 1.5 T. Nery et al.1 also found that NAA levels negatively
correlated to the length of illness in MDD patients (r = -0.460, P = 0.003) and they found
gender differences in PCr + Cr concentrations.
Our group measured metabolite levels in a 1.5 × 1.0 × 1.0 cm voxel in the left anterior
cingulate using 1H MRS at 4 Tesla.2 In contrast to Nery et al.,1 our methods allowed the
measurement of Glu and Gln separately. The data shown in Figure A-1, was taken from 6
depressed patients with psychotic symptoms and 3 likely bipolar patients with a mixed
state with psychotic symptoms. Sixteen first episode schizophrenia patients and 16
controls matched to the schizophrenic group on which we have previously reported were
included for comparison.2 All patients were drug naïve. Three of 16 data sets from
schizophrenia patients were excluded. These 3 spectra were unusable because of the
subjects involuntary movements and/or excessive breathing during the scan.
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Figure A-1: Metabolite levels in schizophrenia, control, and mood disorder.
Metabolite levels measured by proton magnetic resonance spectroscopy from 1.5cm3
in the left anterior cingulate. Error bar represents the group standard deviation. a,
SZ vs. DEP (unpaired two-tailed t-test, t = 2.084, P = 0.055); b, CONT vs. SZ
(t = 2.373, P = 0.025); c, SZ vs. DEP (t = 2.267, P = 0.041); d, group effect in
multivariate test (F = 3.619, P = 0.037).
Group: CONT, normal control; DEP, depressed patients with psychotic symptoms;
SZ, schizophrenia. Metabolites: Cho, choline; Gln, glutamine; Glu, glutamate; Myo,
myo-inositol; NAA, N-acetylaspartate; tCr, total creatine.

The three-group univariate F, 2/35, corresponding to these differences in Gln levels was
3.619 (P = 0.037). LSD post-hoc test was performed in each pair of the groups (twotailed, α = 0.05). 1H MRS metabolite levels in 9 mood disordered patients before
treatment were not significantly different from controls. Although the sample was small,
our result and those of the MDD study1 suggest there may be no significant differences in
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1H MRS metabolites in frontal areas between depressed patients and healthy controls.
However, there may be differences between depressed patients with psychotic symptoms
and schizophrenic patients. We observed significantly decreased Gln levels (t = 2.494,
P = 0.019, d.f. = 1,35) and a trend toward elevated Glu (t = 1.914, P = 0.068, d.f. = 1,35) in
mood disordered compared to schizophrenic patients in the left anterior cingulate.
Moreover, Gln levels in schizophrenia patients were significantly lower than controls
(t = 2.150, P = 0.040, d.f. = 1,35). These results suggest that the mechanisms of mood
disorders and schizophrenia are different in spite of some overlap in clinical symptoms.
Glutamatergic metabolites have been found to be generally decreased in depressed
patients compared to controls and increased compared to controls in studies of bipolar
patients.3,4 Nery et al.1 point to a number of reasons for differences between studies
including sample characteristics, acquisition and post-processing parameters. The Nery et
al. study1 also points out the need for publication of negative findings which are too often
not reported. We observed that mood disordered patients differ from schizophrenia, but
not from controls. If the comparison had only been made between mood disordered
patients and controls, then this negative result may not have been reported. This
illustrates the need for comparative psychiatric groups to parse out findings related to
psychosis from those unique to MDD.
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Appendix B: Description of imaging, spectroscopy, preprocessing, fitting and quantification
Data were acquired with a 4.0 Tesla Varian (Palo Alto, California, USA)/Siemens
(Erlangen, Germany) whole body scanner with a Varian Unity Inova console, located at
the Centre for Functional and Metabolic Mapping of the Robarts Research Institute,
London, Ontario, Canada. A circularly polarized transmit and receive head coil was used.
Global shimming was manually performed with linear and 2nd order shim coils and
followed by T1-weighted transverse anatomical images (three-dimensional magnetization
prepared fast low angle shot (MP-FLASH) sequence, repetition time (TR) = 11 ms, echo
time (TE) = 6.4 ms, inversion time (TI) = 500 ms, flip angle = 30 degrees, 64 slices, matrix
256 × 256, 0.78 × 0.78 mm resolution, field of view = 20 cm, slice thickness = 2.75 mm).
Using those T1-weighted images, the 10 × 15 × 10 mm (right-left, anterior-posterior,
inferior-superior direction) 1H spectroscopy volumes were positioned at the left anterior
cingulate gyrus (Brodmann Area (BA) 32) and the left thalamus.
Magnetic resonance spectroscopy data were obtained with a single voxel stimulated echo
acquisition mode (STEAM) sequence (TE = 20 ms, mixing time (TM) = 30 ms,
TR = 2000 ms, dwell time = 500 µs, 8 step phase-cycling). The power of the 90-degree
radio frequency pulses and the CHESS water suppression pulses were optimized for each
voxel. After local shimming, water suppressed data (256 averages) followed by water
unsuppressed data (16 averages) were collected. Data post processing included zero order
eddy current correction (ECC) and line shape correction with the QUECC technique.1
The remnant water resonances in the water suppressed spectra were subtracted with the
Hankel-Lanczos singular value decomposition algorithm.2 Water suppressed spectra were
fit through an in-house software Fitman program2,3 to the first 1024 data points (512 ms)
in the time domain using a priori knowledge. Our model is based on in vitro
measurements from twelve metabolites plus literature values for eleven macromolecules
added to the a priori knowledge.4,5 Metabolite concentration levels were quantified with
equations6 that included the ratio to water concentration in each spectroscopy voxel. The
voxel water concentration depends on the voxel fraction of gray matter, white matter, and
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CSF along with the water content of each of these tissues. The measured water signal was
therefore corrected by the voxel’s fractional tissue content and assumed literature values
for the water content of each tissue type (gray matter 81%, white matter 71%, CSF
100%). Fractional tissue content was measured from semi-automated segmentation of the
voxel location within the 3D T1-weighted image set as in our previous study.6
Quality of each MR spectrum was evaluated with using Visual Appreciation Scale (from
1 to 5) as well as Baseline and Artefact Scale (from A to E), introduced by Théberge et
al.6 We excluded the spectra in which the gamma-glutamate peak (2.35 ppm) was not
identified and/or severe hashing was seen in a part of the spectra (i.e. rating lower than
5B). Only metabolites with a group coefficient of variation (group CV = (group standard
deviation / group mean) × 100%) less than 75% are reported. Group CV less than 75% in
the normally distributed samples means that 10% of the samples have a chance to be
negative values, which never emerge in our fitting procedure. This criterion protects the
statistical analysis from the metabolites which reach the lower detection threshold. We
elected not to use a criteria based on percent Cramér–Rao lower bound (CRLB) since
CRLB are only a portion of the total inter-individual variability of the data. It is the total
inter-individual variability (group standard deviation) that determines the final ability to
distinguish between two groups (a.k.a, SDD = smallest detectable difference). Metabolites
survived from the criterion are NAA, glutamate (Glu), glutamine (Gln), choline (Cho),
total creatine (tCr), myo-inositol (Myo) in the anterior cingulate and the thalamus, taurine
(Tau) and scyllo-inositol (Syl) in the thalamus only. The “total glutamatergic
metabolites” (tGL) refers to a sum of Glu and Gln levels measured individually. It should
be noted that tGL is different from Glx, which is commonly used in the spectroscopy
literature. Glx has an investigator-dependent definition which can refer to a variety of
quantities. Often, it refers to the integrated spectral area encompassing the peaks from the
3C and 4C multiplets of Glu, Gln, GABA (gamma-aminobutyric acid), the aspartyl
moiety of NAA and NAAG, the glutamate moiety of NAAG as well as signals from
macromolecules. The concept of Glx was useful in the context of overlapping peaks at
lower field strengths (1.5 T) and was used by many of the earlier studies where separate
quantification of these metabolites may have been more difficult.
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Appendix C: Sample spectra

Figure C-1: Fitted in vivo MR spectra
Fitted spectra with 2Hz line broadening collected from the left thalamus in a
schizophrenia patient at NT (a) and at 80 month assessment (b). Preprocessed
spectrum (gray line) with fit (solid line) on the top, corresponding metabolite
components in the middle, and the residual shown below. The boxed regions
indicated in (a) and (b) are magnified in (c) and (d) showing the glutamate (dotted
line) and glutamine (solid line) components.
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